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Abstract 
Background: There is limited information available about the prevalence of Metabolic 
Syndrome (MetS), its trend over time and its predisposing risk factors according to 
different definitions in Canadian adults. No studies have compared the ability of the 
National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) and 
the International Diabetes Federation (IDF) definitions to predict Cardiovascular Disease 
(CVD) mortality among Canadian adults.  
Objectives:   
a) To examine the age and sex specific prevalence of the Metabolic Syndrome in 
Canadian adults by using the ATP III and the IDF definitions.  
b) To examine the risk factors for Metabolic Syndrome in Canadian adults by using the 
ATP III and the IDF definitions.  
c) To examine the association between Metabolic Syndrome and cardiovascular disease 
mortality in Canadian adults by using the ATP III and the IDF definitions. 
Methods: The Canadian Heart Health Survey was a cross-sectional probability  
sample survey conducted in all 10 Canadian provinces between 1986 and 1992. 
The first two studies in this thesis were based on individuals for whom full 
anthropometric measurements were obtained and for whom data on all components of 
MetS were available (provinces of Alberta, Manitoba, Ontario, Quebec and 
Saskatchewan). Statistics Canada linked the CHHS data set to Canadian Mortality 
Database. The third study was based on three provinces (Alberta, Manitoba, and 
Saskatchewan) for whom full anthropometric measurements, mortality data, and data on 
all components of MetS were available.  MetS was defined according to ATP III and IDF 
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definitions. A weighted analysis using SPSS PASW Complex Samples (version18) was 
used to conduct stepwise logistic regression analysis to identify risk factors significantly 
associated with MetS (p < 0.05). Cox-regression analyses using the STATA (version11) 
was conducted to predict CVD mortality.  
Results: According to ATP III, 17.9% and 15.3% of men and women have MetS, while 
according to IDF, 23.8% and 17.3% of men and women have MetS, respectively. Kappa 
agreement between the definitions is 72 % for men and 80% for women (p≤0.05). Older 
age and low level of physical activity are significant risk factors for the MetS regardless 
of gender and definition. Higher level of education and alcohol consumption are 
additional significant protective factors for women, whereas retirement and being 
unemployed are additional significant risk factors for men. The hazards of death due to 
CVD events in women with the syndrome according to the ATP III and the IDF 
definitions are 3.96(1.30-12.09) and 2.56 (1.32-4.97), respectively. The comparable 
numbers for men are 2.21(1.16-4.02) and 2.50(1.50-4.17). 
Conclusion:  In Canadian adults the prevalence of MetS is higher when the IDF 
definition is applied but the metabolic derangement of individuals identified is less 
severe. Demographic, socio economic factors, and lifestyle habits are significantly 
associated with MetS among the Canadian adults. The ATP III definition predicts CVD 
mortality better in women, while the IDF definition predicts CVD mortality better in 
men.  
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1.Introduction  
1.1. Background  
 
In 1920, Kylin, a Swedish physician, described, for the first time, the concept of 
Metabolic Syndrome as a clustering of hypertension, hyperglycemia, and gout  
(1).  An association between upper body adiposity (android or male obesity) and some 
metabolic abnormalities present in patients with type 2 diabetes and cardiovascular 
disease was observed by Vague in 1947 (2).Reaven outlined the clinical importance of 
the Metabolic Syndrome  for the first time approximately 40 years ago.  He did not 
consider obesity as a risk factor for the development of the Metabolic Syndrome but 
described the syndrome as a cluster of metabolic abnormalities in which insulin 
resistance had a “causative role” and called it Syndrome X (2-4).   
 
The Metabolic Syndrome has been identified by different names, such as” syndrome X”, 
the “insulin resistance syndrome” and the “deadly quartet” over the past few decades 
(1,2). As researchers begun to accept the concept of Metabolic Syndrome, there was a 
need to define it. As number of organizations developed different definitions over the 
past decades. Although several definitions have been proposed and they include different 
details, the essential components of the Metabolic Syndrome are the same: glucose 
intolerance, obesity, hypertension and dyslipidemia (1,2,5,6).  
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1.2. Definitions of Metabolic Syndrome  
The World Health Organization (WHO) published the first definition in 1999, as shown 
in table-1 (2,5,7). In this definition, attention was drawn to the biological and 
physiological description of insulin resistance (3).  This definition had several limitations. 
Measuring insulin sensitivity with the highly complex euglycemic clamp was one of the 
most important limitations. Indeed, using a euglycemic clamp to measure insulin 
sensitivity was not easily applicable to clinical practice or epidemiological studies (2).  
Another limitation of the WHO definition was inclusion of individuals with diabetes 
which lead to limits its value in identifying individuals who are at risk of developing 
diabetes (2).  
 
Table 1. World Health Organization definition of the Metabolic Syndrome   
Insulin resistance, identified by 1 of the following: 
 Type 2 diabetes 
 Impaired fasting glucose 
 Impaired glucose tolerance 
 or for those with normal fasting glucose levels (<110 mg/dL), glucose uptake 
below the lowest quartile for background population under investigation under 
hyperinsulinemic, euglycemic conditions 
Plus any 2 of the following: 
 Antihypertensive medication and/or high blood pressure ( 140 mm Hg systolic or 
90 mm Hg diastolic) 
 Plasma triglycerides (TG)  150 mg/dL ( 1.7 mmol/L) 
 High Density Lipoprotein( HDL) cholesterol <35 mg/dL (<0.9 mmol/L) in men or 
<39 mg/dL (1.0 mmol/L) in women 
 BMI >30 kg/m2 and/or waist: hip ratio >0.9 in men, >0.85 in women 
 Urinary albumin excretion rate 20 µg/min or albumin:creatinine ratio 30 mg/g 
 
 
Subsequently, since applying the WHO definition was difficult, the European Group of 
the study Insulin Resistance (EGIR) modified the WHO definition in 1999 (8). They 
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called it insulin resistance syndrome and similar to the WHO definition considered 
insulin resistance as a key component of the disease. They restricted their definition to 
the subjects without diabetes because they believed that measuring insulin resistance in 
diabetic patients was neither reliable nor practical. They also explained that measuring 
fasting insulin is more practical than measuring insulin resistance, so they included 
measuring fasting insulin as a component in the definition. Indeed, they excluded 
“impaired glucose tolerance” or “impaired fasting glycemia” as a requirement for 
diagnosing the syndrome. They included waist circumference as the measurement for 
adiposity because they believed waist circumference was a better indicator for abdominal 
obesity than BMI and waist-to-hip ratio. They modified the cut-off points for 
hypertension, triglycerides, and high-density lipoprotein based on the recommendation of 
European Task Force (Table 2). They also argued that because there was not sufficient 
evidence to show a strong relationship between Metabolic Syndrome and 
microalbuminuria, so this component should not be included in the definition (1-3,5,8,9). 
Table 2. European Group of the study Insulin Resistance definition of the Metabolic 
Syndrome  
Insulin resistance* or hyperinsulinemia (only non-diabetic subjects) 
 
Plus two of the following: 
Central obesity: waist circumference 94 cm (M), 80 cm (F) 
Raised TG ( 2.0 mmol/L) and/or low HDL-cholesterol (<1.0 mmol/L) or treatment 
Fasting/2 h plasma glucose 6.1/7.8 mmol/L but <7.0/11.1 mmol/L 
Raised arterial blood pressure ( 140/90 mmHg) or treatment 
 
*defined as the top quartile of fasting insulin in the non-diabetic population 
 
 
In 2001, the National Cholesterol Education Program of the USA developed the ATP III 
definition. In this definition all the components had equal importance and they excluded  
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In 2001, the National Cholesterol Education Program of the USA developed the ATP III 
definition. In this definition all the components had equal importance and they excluded  
any measurement of insulin resistance and focused more on cardiovascular disease risk 
factors. Each of the diagnostic criteria was justified based on its prevalence among 
American people. In the definition, they applied the new cut-off points for waist 
circumference as the measurement of abdominal adiposity. They explained that men and 
women develop several metabolic abnormalities when their WC is greater that 102 and 
88 cm, respectively (3,10). In fact, there was a shift from pathophysiological to clinical 
features in the definition their definition was easy to apply in clinical practice and 
epidemiological studies, and so became popular over the last few years (Table 3) 
(2,3,5,6). One of the most important criticisms of their definition was applying the higher 
cut-off value for waist circumference compared to two previous definitions. 
 
Table 3. Adult Treatment Panel III definition of the Metabolic Syndrome  
3 or more of the following: 
1. Abdominal obesity: waist circumference ≥102 cm in men and ≥88 cm in women;   
2. Hypertriglyceridemia: ≥150 mg/dL (1.7 mmol/L);  
3. Low HDL cholesterol: <40 mg/dL (1.03 mmol/L) in men and <50 mg/dL (1.30 
mmol/L) in women;  
4. High blood pressure: 130/85 mm Hg;  
5. High fasting glucose: 110 mg/dL ( 6.1 mmol/L) 
 
In 2004, the American College of Endocrinology (AACE) modified the ATP III 
definition because it believed insulin resistance was a key component in developing 
Metabolic Syndrome. Their definition focused on the pathophysiological cause of insulin 
resistance. It described two categories of risk factors. The first group was those risk 
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factors which help researchers and clinicians to identify individuals who are more likely 
to have insulin resistance. They explained these factors as “identifying abnormalities”: 
including elevated triglyceride, reduced HDL, elevated blood pressure, and elevated 
fasting and post load glucose. The second group consisted of those risk factors which 
increase the chance of developing of Metabolic Syndrome , such as obesity, family 
history of diabetes, hypertension, or CVD, non –European ancestry, age greater than 40 
years, sedentary lifestyle, personal history of gestational diabetes or glucose intolerance, 
coronary heart disease, hypertension, polycystic ovarian syndrome, or  non-alcoholic 
fatty liver disease.  One of the most important criticisms of their definition was not 
including obesity as an ““identifying abnormality”. In fact, their justification was that 
obesity is not a consequence of insulin resistance, but it is a contributing factor to the 
development of insulin resistance.  Compared to the WHO and the EGIR definitions, the 
AACE definition did not include hyperinsulinemia as a component in their definition (1-
3,5).  
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Table 4. American College of Endocrinology criteria for diagnosis of the Insulin 
Resistance Syndrome* 
Identifying abnormalities:  
 
 Elevated triglycerides ≥ 150 mg/dL (1.69 mmol/L) 
 Low HDL cholesterol 
 Men <40 mg/dL (1.04 mmol/L) 
 Women <50 mg/dL (1.29 mmol/L) 
Elevated blood pressure 130/85 mm Hg 
Glucose:  
 2-Hour post glucose challenge >140 mg/dL  
 Fasting glucose Between 110 and 126 mg/dL 
 
Other risk factors: obesity, family history of type 2 diabetes, hypertension, or CVD, 
Sedentary lifestyle, Advancing age, Ethnic groups, Personal history of gestational 
diabetes or glucose intolerance, coronary heart disease, hypertension, polycystic ovarian 
syndrome, non-alcoholic fatty liver disease  
 
*Diagnosis when individual has risk factors and at least two of the identifying 
abnormalities 
 
In 2005, the International Diabetes Federation (IDF) developed a new definition of the 
Metabolic Syndrome of which central obesity, as measured by waist circumference, was 
an essential component (Table 5a, b). Their aim was to identify individuals at the higher 
risk of developing diabetes and vascular events, and to develop a practical definition 
which can be used in both clinical practice and research (3).  The essential components of 
the ATP III definition were included because they were easy to apply in clinical practice 
(9). It also adopted the same threshold for triglycerides, HDL cholesterol, blood pressure, 
and plasma glucose as the ATP III definition. The major difference between the IDF and 
the ATP III definition was the inclusion of waist circumference as a key component. The 
IDF definition proposed different cut-off values for waist circumferences according to 
ethnic background of individual in contrast with single, high cut-off point under the ATP 
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III definition. The IDF argued that there is a strong association between waist 
circumference, cardiovascular disease, and other components of Metabolic Syndrome, 
and they also believed that abdominal obesity was the earliest step in developing of 
Metabolic Syndrome. As a result, waist circumference should be considered a principal 
risk factor. It recommended the ethnic-specific waist circumference. Indeed, they 
believed that the cut-off value for abdominal obesity should be different between Asians 
and other populations because several studies confirmed that the Asian population 
developed diabetes and CVD with at the lower level of abdominal adiposity than the 
European population. It defined different cut-off values for different ethnicity based on 
the studies which investigated the relationship between waist circumference and other 
components of the Metabolic Syndrome among different populations (2). However, one 
of the most important criticisms of their definition was the exclusion of individual who 
are metabolically abnormal but do not have abdominal obesity. The IDF also argued 
explained that abdominal obesity and high triglycerides are highly correlated with insulin 
resistance and that there are some difficulties in measuring insulin sensitivity in clinical 
practice. Thus, insulin sensitivity should be excluded from the definition of the Metabolic 
Syndrome (2,3,6). They also suggested that further studies are needed to investigate the 
other criteria which should be included in the definition of the Metabolic Syndrome. 
They listed those criteria in their reports which included: tomographic assessment of 
visceral adiposity and liver fat, biomarkers of adipose tissue, apolipoprotein B, LDL 
particle size, formal measurement of insulin resistance and an oral glucose-tolerance test, 
endothelial dysfunction, urinary albumin, inflammatory markers, and thrombotic markers 
(3). 
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Table 5a. International Diabetes Federation definition of the Metabolic Syndrome  
According to the new IDF definition, for a person to be defined as having the Metabolic 
Syndrome  they must have: 
 
Central obesity (defined as waist circumference* with ethnicity specific 
values) 
Plus any two of the following four factors: 
Raised triglycerides:  ≥150 mg/dL (1.7 mmol/L) or specific treatment for this lipid 
abnormality 
Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 
mmol/L) in females or specific treatment for this lipid abnormality 
Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
Raised fasting plasma glucose: (FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously 
diagnosed type 2 diabetes. If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly 
recommended but is not necessary to define presence of the syndrome. 
 
 
Table 5b.  Ethnic group specific values for waist circumference 
Country/Ethnic group Waist circumference 
Europids 
In the USA, the ATP III 
values (102 cm male; 88 
cm female) are likely to 
continue to be used for 
clinical purposes 
Male ≥94 cm 
Female ≥ 80 
South Asians 
Based on a Chinese, 
Malay and Asian-Indian 
population 
Male ≥90 
Female ≥80 
Chinese Male ≥90 
Female ≥80 
Japanese Male ≥90 
Female ≥80 
Ethnic South and Central 
Americans 
Male Use South Asian 
recommendations until 
more specific data are 
available 
Female 
Sub-Saharan Africans Male Use European data until 
more specific data are 
available 
Female 
Eastern Mediterranean 
and Middle East (Arab) 
populations 
Male Use European data until 
more specific data are 
available 
Female 
 
 9 
In 2005 the National Cholesterol Education Program of the USA modified the ATP III 
definition, which was developed in 2001. As in the original definition all the components 
had an equal importance, but now included individuals receiving treatment for elevated 
triglycerides, elevated blood glucose, hypertension, and reduced HDL cholesterol. In the 
modified definition, the threshold for fasting plasma glucose was reduced from 
6.1mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL). This modification was based on the 
updated definition of impaired fasting glucose by the American Diabetes Association. 
(9,11). In the updated version, although the committee explained that different cut-off 
points might be used bases on the ethnicity, they did not apply these cut-off points. In the 
present thesis when we refer to the ATP III definition, we mean the updated version of 
the definition.  
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Table 6. Updated Adult Treatment Panel III definition of the Metabolic Syndrome   
3 or more of the following: 
1. Abdominal obesity: waist circumference ≥102 cm in men and ≥88 cm in women; *  
2. Hypertriglyceridemia: ≥150 mg/dL (1.7 mmol/L); or drug treatment for elevated 
TG** 
3. Low high-density lipoprotein (HDL) cholesterol: <40 mg/dL (1.03 mmol/L) in 
men and <50 mg/dL (1.30 mmol/L) in women; or drug treatment for reduced 
HDL * 
4. High blood pressure: 130/85 mm Hg; or drug treatment for hypertension  
5. High fasting glucose: 100 mg/dL ( 6.1 mmol/L); or drug treatment for elevated 
glucose  
 
* Some US adults of non-Asian origin (e.g., white, black, Hispanic) with 
marginally increased waist circumference (e.g., 94–101 cm [37–39 inches] in 
men and 80–87 cm [31–34 inches] in women) may have strong genetic 
contribution to insulin resistance and should benefit from changes in lifestyle 
habits, similar to men with categorical increases in waist circumference. Lower 
waist circumference cut point (e.g., _90 cm [35 inches] in men and _80 cm [31 
inches] in women) appears to be appropriate for Asian Americans. 
 
** Fibrates and nicotinic acid are the most commonly used drugs for elevated TG and 
reduced HDL cholesterol. Patients taking 1 of these drugs presumed to have high TG and 
low HDL. 
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In 2009, the IDF and the National Cholesterol Education Program groups attempted to 
provide unified criteria for diagnosis of MetS. They agreed that WC should not be a 
prerequisite to diagnose the Metabolic Syndrome, and that its threshold should be defined 
based on the population ethnicity. In fact, they applied the ATP III definition with the 
IDF cutoff points for WC (table7a, b) (12).   
Table 7a. Unified definition of the Metabolic Syndrome  
3 or more of the following: 
 
Central obesity* (defined as waist circumference* with ethnicity specific values) 
Raised triglycerides:  ≥150 mg/dL (1.7 mmol/L) or specific treatment for this lipid 
abnormality 
Reduced HDL cholesterol**: < 40 mg/dL (1.03 mmol/L) in males < 50 mg/dL (1.29 
mmol/L) in females or specific treatment for this lipid abnormality 
Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
Elevated fasting glucose***: ≥ 100 mg/dL (5.6 mmol/L), or  treatment of elevated 
glucose 
*It is recommended that the IDF cut points be used for non-Europeans and either the IDF 
or AHA/NHLBI cut points used for people of European origin until more data are 
available. 
**The most commonly used drugs for elevated triglycerides and reduced HDL-C are 
fibrates and nicotinic acid. A patient taking 1 of these drugs can be presumed to have 
high triglycerides and low HDL-C. High-dose _-3 fatty acids presume high triglycerides. 
** *Most patients with type 2 diabetes mellitus will have the Metabolic Syndrome by the 
proposed criteria. 
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Table 7b.  Ethnic group specific values for waist circumference by organization 
 
 
 
 
 
Population 
 
 
 
 
 
Organization (Reference) 
Recommended Waist 
Circumference threshold for 
abdominal obesity 
Men Women 
Europid  IDF ≥94 ≥80 
Caucasian  WHO ≥94 ≥80 
United States AHA/NHLBI (ATP III) * ≥102 ≥88 
Canada Health Canada ≥102 ≥88 
European 
 
European Cardiovascular 
Societies 
≥102 ≥88 
Asian (including Japanese) IDF ≥90 ≥80 
Asian WHO ≥90 ≥80 
Japanese Japanese Obesity Society ≥85 ≥90 
China Cooperative Task Force ≥85 ≥80 
Middle East, Mediterranean IDF ≥94 ≥80 
Sub-Saharan African IDF ≥94 ≥80 
Ethnic Central and South 
American 
IDF ≥90 ≥80 
*Recent AHA/NHLBI guidelines for Metabolic Syndrome recognize an increased risk for 
CVD and diabetes at waist-circumference thresholds of _94 cm in men and _80 cm in 
women and identify these as optional cut points for individuals or populations with 
increased insulin resistance. 
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1.3. Pathophysiology of the Metabolic Syndrome  
 
 Two hypotheses regarding the underlying pathophysiological processes which lead to the 
development of the Metabolic Syndrome have been developed (insulin resistance and/or 
hyperinsulinemia versus abdominal obesity).  
 
The most accepted hypothesis among the researchers regarding the pathophysiology of 
the Metabolic Syndrome identifies central role plays by insulin resistance. It has been 
defined as a defect in insulin action whereby normal levels of insulin cannot trigger the 
signal for absorption of glucose which subsequently leads to hyperinsulinemia. Free Fatty 
acid (FFA) which is released from adipose tissue mass is a major contributor in 
development of insulin resistance. FFA in the liver triggers the production of glucose, 
triglycerides and also increases the secretion of very low density lipoproteins (VLDL). 
Associated lipid abnormalities consist of increasing in the level of low density 
lipoproteins (LDL) and decreasing in the level of high density lipoprotein (HDL). FFA 
also inhibit insulin-mediated glucose uptake which lead to a reduction in insulin 
sensitivity in muscle. Associated defects include reduction in transformation of glucose to 
glycogen and an increase in lipid accumulation in form of triglyceride (TG) in the liver. 
Increases in amount of circulating glucose and FFA will lead to an increase in secretion 
of insulin from pancreas which subsequently leads to hyperinsulinemia.  
Hyperinsulinemia stimulates the lipolysis phase and produce more fatty acids which also 
inhibit the antilipolytic effect of insulin which subsequently create additional lipolysis 
(1). 
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Figure 1.  Pathophysiology of the Metabolic Syndrome (13) 
 
I. Dyslipidemia 
Insulin resistance at the adipocytes leads to the increase in release of FFA into circulation 
by blocking the inhibitory effect of insulin on adipocyte lipolysis. Subsequently, FFA 
will be delivered to the liver and muscle. Increased FFA flux to the liver stimulates 
production of very low-density lipoproteins (VLDL) which lead to hypertriglyceridemia. 
In addition, VLDL stimulates the action of cholesteryl ester transfer protein (CTEP) 
which leads to exchange of TG for cholesteryl ester from low-density and high density 
lipoproteins. Lipoprotein or hepatic lipase act on TG-enriched LDL and create smaller 
and denser LDL.  Apolipoprotein A-I dissociates from TG-enriched HDL and is exerted 
in the kidney which reduce the available HDL for reverse pathway. This series of actions 
will lead to high TG, low HDL, and high small dense LDL (13,14). 
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II. Glucose intolerance 
Defects of glucose metabolism in insulin-resistant individuals include two deficiencies:  
a) inability to suppress gluconeogensis in liver and muscle which lead to failure of 
suppression of glucose production b) inability to mediate glucose uptake in insulin 
sensitive tissues such as muscle and adipose tissue. To compensate for these defects, 
pancreatic beta cells secrete more insulin to maintain euglycemia. On the other hand, 
prolonged hyper function of pancreatic beta cells can lead to “beta cell exhaustion’ which 
subsequently leads to hyperglycemia. As discussed previously, FFA can stimulate insulin 
secretion but is has been documented that prolonged exposure to high level of FFA can 
lead to fall in secretion of insulin which leads to hyperglycemia and subsequently leads to 
insulin resistance (1,13). 
 
III. Hypertension  
Insulin resistance may produce hypertension through a variety of mechanisms. FFA can 
cause vasoconstriction in the circulatory system by increasing the production of 
angiotensinogen.  Insulin reduces nitric oxide which causes vasodilatation in vessels in 
normal weight people and also promotes the reabsorption of sodium from the kidney. In 
individuals with insulin resistance, the sodium reabsorption effects are preserved but the 
vasodilatory function will be lost. This can lead to hypertension. In addition, insulin 
stimulates the activity of the sympathetic nervous system. Through these mechanisms, 
insulin resistance promotes the development of hypertension (1,13).  
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IV. Insulin resistance and obesity 
It has been well documented that variations of fat distribution have differing effects on 
insulin action. Independent of total adiposity, that there is a strong association between 
visceral adiposity and insulin resistance (15). In fact, an increase in visceral adipose 
tissue leads to a higher rate of flux of adipose tissue-derived FFA to the liver, which leads 
to insulin resistance (1).Yet, whether this relation  is a causal relationship is still 
controversial (15). Abdominal subcutaneous fat release lipolysis products, which avoid 
glucose production lipid synthesis, and secretion of prothrombotic proteins. Although 
type of fat distribution is important, differentiation of visceral vs subcutaneous abdominal 
adiposity is not part of the clinical diagnosis of the Metabolic Syndrome (1). 
 
V. Abdominal Obesity and Metabolic Syndrome  
It has been reported that visceral adiposity leads to insulin resistance. In fact, 
accumulation of visceral adipose tissue will lead to impaired FFA metabolism because 
visceral adipocytes are resistant to antilipolytic effect of insulin and they also can cause 
impaired FFA etherification. Thus, there will be high flux of FFA into the liver which 
leads to increase secretion of TG, enhanced hepatic production of glucose, and decreased 
hepatic degradation of insulin, which subsequently causes insulin resistance. Moreover, 
viscerally obese patients have a high level of TG-rich lipoproteins which leads to 
transformation of TG from the TG enrichment of LDL and HDL in exchange for 
choelsteryl esteras. Also, hepatic lipase activity is elevated in people with visceral obesity 
which leads to formation of small LDL and HDL particles, which subsequently leads to 
low amount of HDL cholesterol and high amount of small LDL particles. Thus, 
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abdominal obesity leads to insulin resistance, hyperinsulinema, high TG, glucose 
intolerance, low HDL cholesterol, small LDL dyslipidemia (16,17).  
 
1.4. Issues with having different definitions for Metabolic Syndrome   
 
Several studies showed that risk of developing diabetes and cardiovascular disease were 
higher in individuals with the Metabolic Syndrome (18-22).  A detailed literature review 
was done by Cameron et al. The results showed that the prevalence of Metabolic 
Syndrome differed widely between studies because of study design, study population, 
and definitions of the Metabolic Syndrome (Figure 1) (1,5). However, most studies agree 
that the prevalence of Metabolic Syndrome is increasing and Metabolic Syndrome is 
becoming a global problem (3). Several studies compared the prevalence of Metabolic 
Syndrome according to different definitions, and the degree of concordance between 
definitions.  Most these studies agreed that the prevalence of Metabolic Syndrome was 
higher when the IDF definition was applied (3,11,23-27). The use of different definitions 
may lead to confusion in the interpretation the results of epidemiological studies.  Thus, 
there is a need for a standard definition that eliminates the confusion for both researchers 
and clinicians (3,11). The IDF and ATP III groups attempted to harmonize the definition 
of the Metabolic Syndrome in 2009. They agreed that abdominal obesity should not be an 
obligatory component in the definition, and that different cut-off points should be applied 
for WC based on the ethnicity (12).  There is considerable debate about which criteria 
should be used, which definition identifies individuals with more adverse metabolic 
profiles, which is more suitable for clinical practice, which better predicts future CVD 
events, and whether all components of the Metabolic Syndrome should have an equal 
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weight in the definitions (3,24-32). Most previous studies applied the WHO and EGIR 
definitions while more recent studies applied the ATP III and IDF definitions (11).  
 
 
Figure 2. Prevalence of the Metabolic Syndrome according to Adult Treatment Panel 
III definition (1,5) 
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1.5. How to best define the Metabolic Syndrome  
Several definitions have been developed to define the Metabolic Syndrome.  As 
discussed earlier, all these definitions attempted to cluster the key components. In fact, 
two conceptual frameworks have been applied in developing of the definitions.  In one 
paradigm, there was a focus on etiology of the Metabolic Syndrome  which has been 
discussed earlier (abdominal obesity or insulin resistance) (Figure 3a), however, in 
another paradigm, the components were selected based on their statistical strength of 
their association with other components, which subsequently might  identify underlying 
feature (Figure 3b) (33). 
.  
 
Figure 3. Conceptual frameworks for the Metabolic Syndrome definition (33) 
 
Several factors should be considered in developing the definition for the Metabolic 
Syndrome.  These include considering the components which capture individuals with the 
condition, defining the thresholds which identifies abnormalities, defining different 
thresholds in different ethnic groups, and defining the definition which can easily be 
applicable in both clinical practice and research.  As it was discussed earlier, several 
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definitions have been developed during the past years. Applying each of them has some 
benefits and disadvantages. In summary, the WHO definition considers insulin resistance 
as a main cause of the syndrome and a mandatory component. Thus, the WHO definition 
does not include those people who have other criteria but do not have insulin resistance. 
In addition, using the euglycemic clamp to measure insulin resistance is not easily 
applicable in clinical practice and large epidemiologic studies (34). It has been shown 
that there are no absolute criteria which can classify individuals as being insulin resistant 
(34,35). Waist-hip ratio or BMI, which has been considered in the WHO definition, has 
been shown to accurately measure the visceral obesity. Similar to the WHO definition, 
the EGIR definition considers insulin resistance as a mandatory component which also 
leads to the exclusion of individuals who have other criteria but not insulin resistance. 
One of the strengths of EGIR definition is the application of the WC as an indicator for 
visceral adiposity. 
 
The ATP III definition uses measurements which are readily available in clinical practice 
and epidemiological research. This definition does not give any specific notion to 
underlying cause of Metabolic Syndrome (insulin resistance or obesity).However, it has 
been discussed that WC threshold should be different in different ethnic groups. In the 
IDF definition, obesity, not insulin resistance, has been considered as a key factor. Thus, 
the IDF definition does not cover those individuals who are insulin resistant and have 
other metabolic abnormalities but are not abdominally obese. 
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As discussed earlier, having different definitions for the Metabolic Syndrome reflect on 
different conceptual frame works. For researchers and clinicians who consider the 
Metabolic Syndrome as a clinical manifestation of insulin resistance, the WHO and EGIR 
definitions are the more relevant definitions. However, for those who believe that the 
main etiological factor in the development the Metabolic Syndrome is abdominal obesity, 
clustering of those factors associated with abdominal obesity predict development of 
CVD, the ATP III or the IDF definition are felt to be most appropriate. Thus, choosing 
the most appropriate definition can be based on the purpose of defining the Metabolic 
Syndrome. However, among different definitions the highest priority should be given to 
the definitions which can identify people who are at the risk of developing of CVD or 
diabetes because the primary purpose of defining the syndrome was to identify these high 
risk groups (33).  
 
 
 
 22 
1.6. Prevalence of Metabolic Syndrome  
Several studies compared the prevalence of Metabolic Syndrome based on different 
definitions, and also the degree of concordance between definitions (3,11,23,25-27,31,36-
41). Most studies agreed that the prevalence of Metabolic Syndrome was higher when the 
IDF definition was applied.  
 
Sandhofer et al recruited 943 Austrian men aged between 40 and 60 years and 575 
Austrian women aged between 50 and 70 years from “Salzburg Atherosclerosis 
Prevention Program in Subjects at High Individual Risk” (SAPHIR) data base. 
Individuals with diabetes or cardiovascular disease were excluded in the study.  The 
results showed that the prevalence of Metabolic Syndrome in men was 18.7%, 18.9%, 
and 25.8% when the WHO, the ATP III, and the IDF definitions were applied, 
respectively. The comparable numbers in women were 16.2%, 17.0%, and 19.5%, 
respectively. They explained that concordance between the definitions of WHO and IDF 
was 50% and was 67% between the ATP III and IDF definitions (25). 
 
Moebus et al conducted a cross sectional study among 35869 German patients (38.9% 
men, 61.1% women) between the ages of 18 and 99 from general practices in 2005. They 
compared the prevalence of Metabolic Syndrome according to the ATP III (2001), ATP 
III (2005), and the IDF definitions.  Prevalence of Metabolic Syndrome was 22.7% in 
men and 18% in women when the ATP III (2001) definition applied, and 40.3% in men 
and 28.0% in women when the IDF definition applied. Prevalence of the syndrome was 
34.8% in men and 24.8% according to the ATP III (2005) definition.  The kappa 
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agreement between the ATP III (2001) and the IDF definitions was 61% in men and 74% 
in women. Agreement of the ATP (2005) and the IDF definitions was 79 % in men and 
89% in women (11).  
 
In another cross-sectional study among the 10206 Norwegians men and women (Nord-
Trøndelag Health Study) between age of 20 and 89 years by Hildrum et al the prevalence 
of the Metabolic Syndrome was reported (1995-97). The prevalence of Metabolic 
Syndrome was 26.8% in men and 25% in women according to the ATP III definition, and 
29% in men and 30.3% in women according to the IDF definition. Kappa agreement 
between these definitions was 57% in men and 76% in women (23). 
 
 In another cross-sectional study by Olijhoek on 2373 Dutch patients who had vascular 
disease (coronary heart disease, TIA or ischemic stroke, peripheral arterial disease or 
abdominal aortic aneurysm), they reported that the prevalence of the Metabolic 
Syndrome  was higher according to the IDF (52%) than the ATP III definition (41%). 
Their results showed that out of 974 individuals who had Metabolic Syndrome according 
to the ATP definition, only 838 had Metabolic Syndrome by the IDF definition. There 
were 402 individuals who had Metabolic Syndrome according the IDF definition but not 
the ATP III definition. They did not report the kappa agreement between the definitions 
(27).  
 
The DECOD study group (Diabetes Epidemiology: Collaborative Analysis of Diagnostic 
Criteria in Europe) examined 14222 people (6577 men and 7645 women) non-diabetics 
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and 1516 diabetic individuals with Asian origin (Native Asian Indians and Mauritian 
Indians, native Chinese, and native Japanese). The results showed that the prevalence of 
Metabolic Syndrome was higher by applying the IDF definition than the ATP III 
definition. Overall, 1082 men and 1299 women had Metabolic Syndrome by either of the 
definitions in this study. 49% of individuals who had Metabolic Syndrome by the IDF 
definition had Metabolic Syndrome by the ATP III (2001). 68% of individuals who had 
Metabolic Syndrome by the ATP III had Metabolic Syndrome by the IDF. The agreement 
between the definitions was poor in men (Kappa= 36%) and moderate in women 
(Kappa= 58%) (26). 
   
Hadeagh et al in the Tehran Lipid and Glucose study, among 720 Iranian men and 
women older than 65 years, reported that the prevalence of Metabolic Syndrome  was 
50.8%, 41.8% and 41.9% based on the ATP III (2001), the WHO, and the IDF 
definitions. They reported that there was a good agreement between the IDF and the ATP 
III definition (Kappa statistics= 63.4%), and there was low agreement between the IDF 
and the modified WHO definitions (Kappa statistics= 38.3%) (41).  
 
Ford et al obtained the data from the National Health Nutrition Examination Survey 
( 1988-1994), a cross sectional study among 8708 Americans , 4167 men and 4441 
women, aged older than 20 years, reported the age-adjusted prevalence of Metabolic 
Syndrome  in men was 25.1 % (applying the ATP III definition,2001) and 27.6% 
(applying the WHO definition). The comparable numbers in women were 22.7% and 
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20.3%, respectively. The degree of agreement between two definitions was 86.4% and 
86.7% in men and women (37). 
 
Ford et al conducted another study by obtaining the data from the Third National Health 
Nutrition Examination Survey (1999- 2002). In this study they examined 3601 American 
men and women older than 20 years of age. Unadjusted prevalence of Metabolic 
Syndrome for men and women was 33.7% and 35.4%, applying the ATP III definition 
2005, and was 35.4% and 38.1 % by applying the IDF definition. The degree of 
agreement between definitions was not reported in this study (38). 
 
Cheung et al merged data from two cycles of the Nutrition Examination Survey in the 
USA (1999-2000 and 2001-2002), and estimated the prevalence of Metabolic Syndrome 
using the IDF, the ATP III, and the WHO definitions. They examined 3584 Americans 
older than 20 years of age. The prevalence of Metabolic Syndrome in men was 20.1, 
33.6, and 39.9, and in women the prevalence of the syndrome was 18.6%, 35.3%, and 
38% according to the WHO, ATP III, and IDF definitions, respectively. They concluded 
that agreement between the IDF and the ATP III definitions in men and women was 89.8 
% and 95.9%, respectively. The degree of agreement between the IDF and WHO 
definitions was reported at 77.1% in men and 79.4% in women (31). The difference in the 
prevalence might be because of different sample size between these studies.  
 
In 2003, Arden et al, analyzed data from the Canadian Heart Health Survey (1986–1992), 
a cross sectional study, which include 7981 Canadians aged 18-64. They reported that the 
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prevalence of Metabolic Syndrome was 17% in men and 13.2 % in women according to 
the ATP III definition (42). Also, Brien et al obtained data from the Canadian Heart 
Health Surveys (1986–1992), and studied 12881 Canadians aged between 18-64.  The 
ATP III definition was applied and the reported prevalence of the Metabolic Syndrome 
was 17.5% in men and 11.2% in women  (36).   
 
Katzmarzyk et al, in a study among 20789 white, non-Hispanic American men aged 20–
83 years from the Aerobics Center Longitudinal Study, concluded that the prevalence of 
Metabolic Syndrome  was higher by the IDF definition(38.6%) than the ATP III 
definition (24%) (40). 
 
Liu et al compared the prevalence of Metabolic Syndrome among three ethnic groups 
(Native Indians, Inuit, and non-aboriginal Canadians) in Canada.  They combined four 
sources of data set: the Northern Indians Chronic Disease Study (NICDS 1986–1987), the 
Manitoba Heart Health Survey (MHHS 1989–1990), the Keewatin Health Assessment 
Study (KHAS 1990–1991), and the Sandy Lake Health and Diabetes Project (SLHDP 
1993–1995). The prevalence of Metabolic Syndrome by the ATP III (2005) definition 
was 30.4% in men and 39.7% in women among Oji-Cree Indians. When the WHO 
definition was applied, the comparable numbers were 32.6% and 34.1%. A moderate 
agreement between the ATP III and the WHO definition was observed (kappa 
agreement= 63%) (3,39) 
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Riediger et al recently published described the prevalence of Metabolic Syndrome in the 
Canadian adults using data from the first Canadian Health Measures Survey, a cross 
sectional study which conducted between 2007 and 2009 (12). Both the ATP III and 
unified criteria have been applied. 1800 individuals was included in their study which 
represent 24 473 500 Canadians. They reported that the prevalence of Metabolic 
Syndrome was 15.9 and 19.5 in men and women according to the ATP III definition, 
respectively. Also, prevalence was 23.4 in men and 22.9 in women based on unified 
definition when lower WC cutoff points applied (WC≥94 in men, WC≥ in women) (43). 
 
Although there is a strong relationship between the Metabolic Syndrome and 
development of cardiovascular disease (21) and cardiovascular disease is one of main 
causes of death in Canada, there is limited information available regarding trends in the 
prevalence of Metabolic Syndrome in Canada.  In addition, to our knowledge, few 
Canadian studies compared the prevalence of Metabolic Syndrome by applying the IDF 
and the ATP III definitions (32,40). Several studies compared the degree of concordance 
between different definitions in the European, American, and Asian populations; 
however, no study that we found investigated the degree of agreement between the IDF 
and ATP definitions in Canada. 
. 
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1.7. Risk factors for Metabolic Syndrome  
Several studies have been conducted to investigate the risk factors for Metabolic 
Syndrome.  It has been shown that the prevalence of the Metabolic Syndrome is age 
dependent. Also, there is a negative association between physical activity and 
socioeconomic status and Metabolic Syndrome, and individuals with the marital distress 
have higher risk of developing the Metabolic Syndrome. It has been shown that the 
association between smoking, alcohol consumption and Metabolic Syndrome is complex.  
 
I. AGE  
Several studies have shown that the prevalence of Metabolic Syndrome was age 
dependent regardless of the definition (23,44-46). Some studies observed that the 
prevalence of Metabolic Syndrome reaches its peak in the seventh decade of life, and 
after that there was a decrease in the prevalence in both sexes or only in men (table 8). 
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Table 8. Association of Metabolic Syndrome with age 
Author  Definition 
of MetS  
used   
Sample population Study design Prevalence 
association  with 
age 
Hildrum,B 
et al (2007) 
IDF  
ATP III 
Norwegians men (n=5101) 
Norwegians men (n=5105) 
Cross-sectional Increase in both 
sexes 
 
Azizi, F et al  
(2003) 
ATP III Iranian men (n=4397 ) 
Iranian women (n=5971) 
Cross-sectional Increase in both 
sexes 
 
Sanisoglu,S.Y 
et al (2006) 
IDF Caucasian men and women 
(n=15468) 
Healthy Nutrition 
for Healthy Heart 
Study /Cross-
sectional 
Increase in both 
sexes with peak 
in seventh 
decade  
 
Hu, G et al 
(2004) 
WHO European men (n=6156)  
European women (n=5356)  
11 prospective 
European cohort 
studies  
 
Increase in both 
sexes with peak 
in seventh 
decade 
 
Adams, R.J. 
et al (2005) 
IDF  
ATP III 
Australian men (n=1988) 
Australian  
women(n=2072) 
Cross-sectional 
study 
Men: increase 
Women: 
increase with a 
peak in seventh 
decade 
 
Li, Z.Y et a 
l(2006) 
ATP III Chinese men (n=8801) 
Chinese  women (n=7541) 
Cross-sectional Men: increase 
Women: 
increases with a 
peak in seventh 
decade 
 
In a cross-sectional study among 10206 Norwegians aged 20-89 years, Hildrom et al used 
the IDF and the ATP III definitions. They found that the prevalence of Metabolic 
Syndrome increased with age in both sexes according to both definitions (23). Azizi et al 
recruited 4397 men and 5971 women older than 20 from the Tehran Lipid and Glucose 
Study. They applied the ATP III definition and found a similar pattern (20,45,47). 
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Sanisoglu et al obtained the data from the Healthy Nutrition for Healthy Heart Study 
which was conducted between 2000 and 2002 in Turkey. They recruited 15468 
Caucasian men and women aged over 30 and applied the IDF definition for the 
syndrome. They found that the prevalence of Metabolic Syndrome was age dependent 
and there was a peak in prevalence in the seventh decade, followed by a decline for both 
sexes (44).  The DECODE Study Group invited 11 prospective European cohort studies 
(Centers in Europe which conducted population-based studies or large studies in 
occupational groups) to participate in their study using the WHO definition. They studied 
6156 men and 5356 women without diabetes aged between 30 and 89 years, and reported 
that the prevalence of Metabolic Syndrome  was age dependent and peaked at the age 70 
and then declined in both sexes, similar to Sanisoglu et al  (20).  
 
Adams et al conducted a cross-sectional study in 4060 Australian men and women older 
than 18 years, and applied the IDF and the ATP III definitions to define the syndrome. 
They found that prevalence of Metabolic Syndrome reached its peak at the seventh 
decade and with decline thereafter in men, but not in women (46). Similar pattern also 
found by Li et al. They conducted a cross-sectional study and applied the ATP III 
definition among Chinese population (8801 men and 7541 women) aged 20–90 years 
between 2003 and 2004.  In this study participants were those who attended medical 
examinations, educational faculties and health officers (47).  
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II. SMOKING   
 
 
There is a debate regarding the magnitude of association between smoking and the 
Metabolic Syndrome.  Several studies reported that smokers are at a higher risk of 
developing Metabolic Syndrome than non-smokers (48-50). They interpreted their results 
as being the result of the association between smoking and some of the components of 
Metabolic Syndrome. Indeed, smoking can elevate blood pressure and triglyceride level, 
decrease HDL- cholesterol level, and impair insulin function (49,51-54). However, other 
studies have shown that smokers had lower prevalence of Metabolic Syndrome (55,56). 
These authors explained their results as being the result of the inverse relationship 
between smoking and obesity (56), which could lead to lower prevalence of the 
Metabolic Syndrome  among smokers (table9) (55).  
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Table 9. Association between Metabolic Syndrome and smoking 
Author  Definition 
of MetS  
used   
Sample population Study design Association with 
smoking 
Park, Y.W 
et al 
(2003) 
ATP III non-Hispanic blacks 
(n=3305),  Mexican 
American (n=3477), 
 non-Hispanic whites 
(n=5581) 
Third National 
Health and Nutrition 
Examination Survey/ 
Cross-sectional 
Risk factor 
Men: 
OR= 1.5(1.1-2.2) 
Women;  
OR=1.8(1.2-2.6) 
 
Zhu, S et 
al (2004) 
ATP III American men( n=5415)   
American women 
(n=5824) 
Third National 
Health and Nutrition 
Examination Survey/ 
Cross-sectional 
Risk factor * 
Men:  
OR= 0.63(0.45-0.90) 
Women:  
OR=0.58(0.41-0.81) 
 
Park, H.S 
et al 
(2004) 
ATP III Korean  men ( n=3937) 
Korean women (n=4713) 
Korean National 
Health and Nutrition 
Examination Survey/ 
Cross-sectional  
Risk factor  
Men:  
OR= 1.4(1.1- 1.8) 
Women:  
OR=0.58 (1.2-2.1) 
 
Lee, W.Y 
et al 
(2005) 
ATP III Korean  men (n=2059) 
Korean  women (n=2282) 
Cross-sectional  Risk factor  
OR=1.9 (1.1-3.7) 
Santos, 
A.C et al 
(2007) 
ATP III  Portuguese women 
(n=1332) 
Portuguese men (n=832) 
Cross-sectional  Protective factor 
Light smokers:  
Women: 
OR=0.32(0.11–0.92) 
Heavy smokers: 
Men: 
OR=0.87(0.32–2.38) 
Women: 
OR=0.65(0.34–1.23) 
 
Onat, A et 
al (2007) 
ATP III Turkish men (n=1674) 
Turkish  women (n=1711) 
Cohort Heavy smokers: 
Men: 
OR= 0.84 (NS) 
Women: 
RR=0.5(0.26-0.94) 
*OR for never smokers 
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Park et al used the data from the Third National Health and Nutrition Examination Survey 
(1988-1994), and applied the ATP III definition to diagnose the Metabolic Syndrome. 
They studied non-Hispanic blacks (n=3305), Mexican American (n=3477), and non-
Hispanic whites (n=5581) older than 20 years of age. They excluded 5964 individuals for 
whom the information about anthropometric measurements and blood studies were not 
available. They found that the odds of having the syndrome was higher for current 
smokers compared to those who had never smoked in both sexes (Men: OR= 1.5; CI: 1.1-
2.2, women; OR=1.8; CI: 1.2-2.6) (48). 
 
Zhu et al obtained data from the Third National Health and Nutrition Examination Survey 
a year after Park et al conducted their study. They studies 5415 American men and 5824 
American women. The purpose of their study was to investigate the lifestyle risk factors 
which were related to the Metabolic Syndrome.  As expected, their results were similar to 
the results of the study by Park et al. They found that individuals who had never smoked 
had a lower odds ratio (OR) for developing Metabolic Syndrome than current smokers in 
both sexes (Men: OR= 0.63; CI: 0.45-0.90, women: OR=0.58; CI: 0.41-0.81) (50).  
 
Park. H et al obtained data from the Korean National Health and Nutrition Examination 
Survey (3937 men and 4713 women). They applied the ATP III definition and 
investigated the lifestyle factors which could put individuals at a higher risk for having 
the Metabolic Syndrome. They found that current smokers individuals had higher odds of 
having the Metabolic Syndrome compared to individuals who had never smoked in both 
sexes (Men: OR= 1.4; CI: 1.1- 1.8, women: OR=0.58; CI: 1.2, 2.1) (49).  
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Le et al conducted a cross-sectional study among Korean individuals (2059 men, 2282 
women) who underwent health check-ups to the Kangbuk Samsung Hospital in Seoul. 
They excluded subjects who received medication from their study.  They defined the 
Metabolic Syndrome by the ATP III definition, and found that the relative risk of having 
the syndrome was higher among smokers than non-smokers (OR: 1.9; CI: 1.1-3.7) (51). 
 
Santos et al conducted a study among Portuguese (1332 women and 832 men) aged 18–
92 years old, and defined the syndrome by the ATP III definition. They found that 
smoking was a protective factor against developing the syndrome. They found that 
women who smoke less than ten cigarettes per day had a lower risk of developing the 
syndrome than non-smokers (OR: 0.32; CI: 0.11–0.92). Also, a similar pattern was 
observed for women and men who smoke between ten and twenty cigarettes per day 
(women; OR: 0.65, CI:  0.34–1.23, men; OR: 0.87; CI: 0.32–2.38), but the association 
was not statistically significant. However, both men and women who smoke more than 
twenty cigarettes per day had a higher risk of developing the Metabolic Syndrome but 
these associations were not significant (55). In a cohort study by Onat et al among 
Turkish adults(1674 men and 1711 women) found that women who smoke heavily had a 
lower risk of developing of Metabolic Syndrome  presumably due to the inverse 
association between obesity and smoking (RR=0.5; CI: 0.26-0.94) (56). 
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III. ALCOHOL COSUMPTION 
The relation between alcohol consumption and components of Metabolic Syndrome is 
complex.  Several studies have reported that alcohol consumption was associated with 
higher HDL-cholesterol in a dose-response manner. A dose-response or J-shaped 
association also found between alcohol consumption and triglycerides. The association 
between alcohol consumption and hypertension was also reported as J-shaped, in fact; 
individuals who drank heavily were at risk of developing high blood pressure.  Some 
contradictory studies showed that alcohol consumption was related to an increased risk of 
obesity both inversely and directly. It has been reported that individuals who were light 
or moderate drinkers had a lower risk of developing diabetes than heavy drinkers; their 
results were explained by the U-shaped relationship between alcohol consumption and 
insulin resistance. In fact, individuals who drank moderately had minimal insulin 
resistance; however, heavy-drinkers and never-drinkers had a higher level of insulin 
resistance (57,58).  
 
There is considerable debate regarding the effect of consuming alcohol on the prevalence 
of Metabolic Syndrome (57,58). Alcohol consumption has been found to be either a risk 
factor (57) or a protective factor (58) in developing the Metabolic Syndrome. However, 
some studies reported that there was no significant association between alcohol 
consumption and development of the Metabolic Syndrome (table 10) (55,59). 
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Table 10. Association between Metabolic Syndrome and alcohol consumption 
Author  Definition 
of MetS  
used   
Sample population Study design  Association with alcohol 
consumption 
Alkerwi, A 
et al (2009) 
ATP III 
EGIR 
WHO 
7 studies 
 
Meta-analysis Protective factor  
Men: 
OR= 0.84(0.75-0.94) 
Women: 
OR=0.75(0.64-0.89) 
 
Fan, A.Z  
et al (2006) 
ATP III American men (n=1150) 
American women 
(n=1668) 
Case-control Risk factor (intensity in 
quartiles) 
OR=1.23(0.91-1.67) 
OR=1.43(1.06-1.91) 
OR=1.60(1.2-2.30) 
 
Park, H.S  
et al (2004) 
ATP III Korean  men ( n=3937) 
Korean women (n=4713) 
Cross-sectional No significant association 
Men: 
15 g/day OR= 0.8(0.7- 1.1) 
15 -day OR=1(0.8-1.5) 
≥30 g/day OR=1( 0.8-1.3) 
Women:  
15 g/day OR= 0.8(0.7- 1.1) 
15 -day OR=0.9(0.5-1.4) 
≥30 g/day OR=1.7(0.9-3.0) 
 
Rosell, M  
et al (2003) 
 Swedish men (n= 2039) 
Swedish women (n= 
2193) 
Cross-sectional No significant association 
Men: 
wine: OR=0.75(0.48 – 1.20) 
beer: OR=0.88(0.55 – 1.41)  
spirits: OR=1.67(0.84 – 3.31)   
mixed OR=0.95(0.65 – 1.39) 
Women: 
wine: OR=0.60(0.40 – 0.91)  
beer: OR= 0.95(0.36 – 2.53) 
spirits: OR= 2.01(0.82 – 4.92) 
mixed: OR= 0.84(0.50 – 1.40) 
 
Santos, A.C 
et al (2007) 
ATP III Portuguese women 
(n=1332) 
Portuguese men (n=832) 
Cross-sectional No significant association 
 
 
Alkerwi et al performed a meta-analysis regarding the relationship between alcohol 
consumption and Metabolic Syndrome. They searched the MEDLINE and EMBASE data 
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bases from 1998 to 2007 to find studies which investigated the relationship between 
alcohol consumption and the prevalence of Metabolic Syndrome. They included only 
those studies which were cross-sectional, conducted in healthy populations, had a clear 
definition for Metabolic Syndrome, reported risk estimates, and quantified self-alcohol 
consumption. Among all 14 studies which met these criteria for eligibility, seven studies 
which did not report the results for both sexes were excluded from their meta-analysis.  
They converted alcohol consumption into a same unit (g/day) because different studies 
used different ways of measuring the alcohol consumption. They concluded moderate 
levels of that alcohol consumption reduced the prevalence of Metabolic Syndrome in 
both sexes (Men: less than 40 g/day, women: less than 20 g/day) (58).  
 
Fan et al conducted a study in the healthy American population (men 1150, women 1668) 
aged 35-79 years and applied the ATP III definition. They investigated the relationship 
between life time drinking patterns and developing the Metabolic Syndrome. They 
measured the lifetime drinking pattern by calculating lifetime total drinks, total years of 
drinking, and intensity of drinking. They categorized each of these variables by quartiles. 
They reported that drinking intensity was a significant risk factor for the Metabolic 
Syndrome in the adjusted analysis. Prevalence ratios for Metabolic Syndrome according 
to the quartiles of intensity, which the first quartile was a reference category, were 1.23 
(0.91-1.67), 1.43(1.06-1.91), and 1.60(1.2-2.30) (57).  
 
Park H et al in a cross-sectional study in Korean population, as explained earlier, applied 
the ATP III definition and found that the consumption of alcohol was not significantly 
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related to the Metabolic Syndrome in both sexes. They categorized alcohol consumption 
into four categories based on the amount of alcohol consumed per day. Never-drinkers 
were considered as a reference category in their analysis. They found following results 
for men: less than 15 g/day (OR= 0.8; CI: 0.7- 1.1), between 15 and 30 g/day (OR=1; CI: 
0.8-1.5), and greater than 30 g/day (OR=1; CI: 0.8-1.3).   They reported the following 
results for women: none, less than 15 g/day (OR= 0.8; CI: 0.7- 1.1), between 15 and 30 
g/day (OR=0.9; CI: 0.5-1.4), and greater than 30 g/day (OR=1.7; CI: 0.9-3.0) (49).  
 
Rosell et al conducted a cross-sectional study among 60 year old Swedish men and 
women who lived in Stockholm County to investigate the association between intake of 
wine, beer, and spirits and Metabolic Syndrome. No significant association was found 
between alcohol consumption and Metabolic Syndrome. The odds of developing the 
Metabolic Syndrome  in men who drinks wine, beer, spirits, and mixed were 0.75 (CI: 
0.48 – 1.20), 0.88 (CI: 0.55 – 1.41), 1.67 (CI: 0.84 – 3.31), and 0.95 (CI: 0.65 – 1.39), 
respectively. The comparable numbers in women were 0.60 (CI: 0.40 – 0.91), 0.95 (CI: 
0.36 – 2.53), 2.01 (CI:  0.82 – 4.92), and 0.84 (CI:  0.50 – 1.40), respectively (60).  
 
In another study, Santos et al studied Portuguese adults, as previously discussed. They 
defined the Metabolic Syndrome by the ATP III definition and gathered information 
about the consumption of different types of alcoholic beverages (ethanol, wine, beer, and 
spirits). They gathered information about the frequency, quantity, duration of 
consumption, and total ethanol intake. They divided each of the alcoholic beverage 
variables into four categories based on the amount of alcohol consumed per day: 0.0 g, 
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0.1–9 g, 10–29 g, and ≥30 g. They reported there was no association between alcohol 
consumption (ethanol, wine, beer, and spirits) and Metabolic Syndrome (55). 
 
IV. PHYSICAL ACTIVITY 
It has been well documented that physical activity can reduce blood pressure, triglyceride 
levels, and abdominal obesity, while it can increase HDL cholesterol level (61-64). Many 
studies have shown that being physically active can reduce the prevalence of the 
Metabolic Syndrome (table 11) (36,49,64-66).  
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Table 11. Association between Metabolic Syndrome and physical activity 
Author  Definition of 
MetS  used   
Sample population Study design Association with 
physical activity  
Rennie, KL  
et al (2003) 
ATP III White European 
(n= 5153)  
Cross-sectional Protective factor 
OR=0.52(0.40-0.67) 
OR= 0.78(0.63-0.96) 
 
Brien, S.E  
et al (2006) 
ATP III Canadian  men 
(n=6406) 
Canadian  women 
(n= 6475)  
Cross-sectional Protective factor 
men: 
OR=0.45(0.29-0.69) 
women: 
0R=0.67(0.44-1.02) 
 
Wamala, SP  
et al (1999) 
WHO 
 
Swedish women 
(n= 300) 
 
Case-control Protective factor* 
OR =2.82(1.46-5.44) 
Ford, E.S.   
et al (2004) 
ATP III American men 
(n=812) 
American  women 
(n=814) 
National Health and 
Nutrition Examination 
Survey/Cross-
sectional 
 
Protective factor 
OR=1.90(1.22-2.97) 
Park, H.S.   
et al (2005) 
ATP III Korean men 
(n=3937) 
Korean women 
(n=4713) 
Cross-sectional Protective factor 
Men: 
OR= 0.6(0.5-0.9) 
Women: 
OR= 0.9(0.6-1.5) 
*OR for individuals who are not active 
 
Rennie et al in a Whitehall II study of civil servants, a cross-sectional study of non-
industrial civil servants aged 45–68 years who worked in London, investigated the 
association between self-reported physical activity and the Metabolic Syndrome. They 
applied the ATP III definition to measure Metabolic Syndrome. They used the Metabolic 
Equivalent of Task (MET) value to define the intensity of the activities. Leisure-time 
physical activity was categorized into moderate and vigorous activity classes. They 
divided the moderate activity into two categories (MET<24 and ≥24 MET hours per 
week), and vigorous activity into four categories (no vigorous activity MET <5, 5 ≤MET 
<12.5, and 12.5≤ MET hours per week). They reported that moderate and vigorous 
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physical leisure-time activity reduced the risk of having the Metabolic Syndrome. OR 
and CI for top categories of vigorous and moderate activity were 0.52 (CI: 0.40, 0.67) 
and 0.78 (CI: 0.63, 0.96) (64). 
 
Brien et al obtained the data from the Canadian Heart Health Survey (1986–1992) to 
investigate the relation ship between physical activity and Metabolic Syndrome. They  
studied 6406 men and 6475 women aged 18–64 and applied the ATP III definition to 
define the Metabolic Syndrome. Participants were considered physically active if they 
were engaged in strenuous activity at least once per week for at least 30 minutes during 
the past 30 days. They found that active individuals had lower odds of developing the 
Metabolic Syndrome than non-active individuals. The odds ratios for Metabolic 
Syndrome for active versus non-active individuals in men and women were 0.45 (CI: 
0.29–0.69) and 0.67 (CI: 0.44–1.02), respectively (36). 
 
Wamala et al conducted a study among healthy Swedish healthy women between the 
ages 30 and 65 years, and defined the Metabolic Syndrome. They applied the WHO 
criteria to assess physical exercise which has four categories: individuals who are 
involved in sedentary leisure activities (Grade I), individuals who do some form of 
activity such as walking or cycling (Grade II), individuals who engage in physical 
activity at least four hours per week (Grade III), and individuals who do vigorous training 
several times a week (Grade IV). They reported that a lack of physical exercise increased 
the odds of developing Metabolic Syndrome (OR= 2.82; CI: 1.46–5.44) (65). 
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Ford et al obtained the data from the National Health and Nutrition Examination Survey 
(1999-2000) including 812 men and 814 women. The ATP III definition was used. They 
asked participants to report the frequency and the duration of moderate or vigorous 
physical activity. They calculated the total minutes that participants were engaged in 
moderate or vigorous physical activity per week and divided it into three categories: 0, 
<150, and ≥150 min/wk. They reported that individuals who did not participate in any 
moderate or vigorous physical activity had higher odds of developing the Metabolic 
Syndrome  than those who engaged in more than 150 min/wk activities in unadjusted 
analysis (OR=1.90; CI: 1.22 to 2.97). However, although the odds were higher after 
adjustment for age, sex, ethnicity, educational status, smoking status, and alcohol 
consumption, the association between physical activity and the Metabolic Syndrome  was 
not significant (OR=1.46; CI: 0.87-2.45) (66). 
 
Park et al used the ATP III definition to define the Metabolic Syndrome and conducted a 
cross-sectional study among 3937 Korean men and 4713 Korean women to investigate 
lifestyle risk factors for Metabolic Syndrome. They obtained information from 
participants about the frequency and extent of physical exercise per week during the past 
month. They split the variable into four groups: not at all, once per week, 2–3 times per 
week, or ≥4 times per week. They adjusted their model for age, residential area, marital 
status, educational status, occupation, smoking status, BMI, alcohol consumption, and 
carbohydrate intake.  They reported that although physical activity decreased the odds of 
developing the Metabolic Syndrome , their association was statistically significant only in 
men who engaged moderate exercise (OR= 0.6; CI=0.5- 0.9) (49). 
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V. MARITAL STATUS 
Some studies suggested that marital distress is associated with cardiovascular mortality 
and morbidity in both women and men (67,68).  There is limited information available 
about the association between Metabolic Syndrome and marital status (table 12). 
Table 12. Association between Metabolic Syndrome and marital status 
Author  Definition 
of MetS  
used     
Sample population Study design Association with  
marital status  
Troxel, 
W.M. et al 
(2005) 
ATP III American women 
(n=413) 
Longitudinal  Marital dissatisfaction: 
OR=3.02(1.46-6.24) 
Divorced: 
OR=2.47(1.02-5.97) 
Widowed: 
OR= 5.82(1.88-18.03) 
 
Park, H.S. 
et al 
(2004) 
ATP III Korean men 
(n=3937) 
Korean women 
(n=4713) 
Cross-sectional Men:  
OR= 0.9 (0.6-1.4) 
Women: 
OR=2 (1.2-3.3) 
 
Troxel et al conducted a prospective study in 413 American women aged 42- 50 years 
and followed up them for 11 years to investigate the presence or absence of Metabolic 
Syndrome  at the last contact. Participants visited five times: baseline, one year 
postmenopausal, and every three years postmenopausal. Participants were asked about 
their marital status and completed a questionnaire to assess satisfaction with marital 
status. They applied the ATP III definition to diagnose the Metabolic Syndrome, which 
was assessed at the baseline and latest follow up visit. They found that maritally 
dissatisfied (OR=3.02; CI: 1.46-6.24), divorced (OR=2.47; CI: 1.02-5.97), and widowed 
women (OR= 5.82; CI: 1.88-18.03) had higher risk of developing the Metabolic 
Syndrome than maritally satisfied women. They justified their results by explaining that 
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not having a relationship or marital distress can act as a psychosocial stressor which can 
increase the risk of developing Metabolic Syndrome. Also, marital distress had a negative 
effect on immune- inflammatory response which can lead to CVD events (69). 
 
Park et al conducted cross-sectional study among 3937 Korean men and 4713 Korean 
women, found that unmarried women had a higher risk of developing Metabolic 
Syndrome  than married women (OR=2; CI: 1.2-3.3), but  no significant association 
between marital status and Metabolic Syndrome  was found in men (49). 
 
VI. SOCIEOECONOMIC STATUS 
Several studies have shown that low socioeconomic status (SES), are determined by 
income or educational level, is a risk factor for the development of cardiovascular disease 
(70). The association between the individual components of the Metabolic Syndrome and 
cardiovascular disease risk factors has been demonstrated by many researchers. A low 
SES was associated with hypertension, impaired glucose tolerance, diabetes, physical 
inactivity, and obesity (48,70-76). Lee et al also explained that low socioeconomic status 
can cause mental and social stress which can subsequently activate hypothalamus-
pituitary-adrenal axis and causing obesity (51).  
 
Most studies agree that there is an inverse relationship between Metabolic Syndrome  and 
the development of socioeconomic status(43,48,65,73,77-80).However, a few studies 
observed that there was no association (table 13) (49,81).   
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Table 13. Association between Metabolic Syndrome and socioeconomic status 
Author  Definition 
of MetS  
used   
Sample population Study design Socioeconomic status 
level of 
education 
income 
Ana, S et al 
(2008) 
ATP III Portuguese men (n=1207) 
Portuguese women (n=755) 
Nutrition  survey/ 
Cross-sectional 
 
Inverse 
 
- 
Loucks, E.B 
et al (2007) 
ATP III American men (n= 7895) 
American women (n= 8821) 
Third National 
Health and 
Nutrition 
Examination 
Survey/ Cross-
sectional 
 
Inverse 
 
- 
Dallongeville, 
J et al (2005) 
ATP III French men (n= 1695) 
 French women (n=1644 
Population 
survey/ Cross-
sectional 
 
Inverse 
 
Inverse 
Brunner, EJ et 
al (1997) 
ATP III British men (n=4978) 
 British women (n=2035) 
 
Cross-sectional - Inverse 
Wamala, SP 
et al (1999) 
 
ATP III Swedish women (n= 300) Case-control Inverse - 
Silventoinen, 
K et al (2005) 
ATPIII 
WHO 
Finnish men (n=864)  
Finish women (n=1045) 
 
Longitudinal Inverse - 
Park, M.J 
et al (2007) 
 Korean men (n=3657) 
Korean women (n=4884) 
Korean National 
Health and 
Nutrition 
Examination 
Survey/ Cross-
sectional 
 
Inverse Inverse 
Park, Y.W 
et al (2003) 
 American men (n=6145) 
American women (n=6680) 
Third National 
Health and 
Nutrition 
Examination 
Survey/ Cross-
sectional 
 
No 
association 
Inverse 
Park, H.S.  
et al (2004) 
ATP III Korean men (n=3937) 
Korean women (n=4713) 
Cross-sectional No 
association 
No 
association 
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Santos et al recruited 1207 men and 755 women from a health and nutrition survey, of a 
representative sample of the non-institutionalized Portuguese, to investigate the 
association between socioeconomic status and the Metabolic Syndrome. They applied the 
ATP III definition to define the syndrome, and considered total years of education (<5, 5-
12, ≥12) and social class (five classes) as indicators of socioeconomic status. Social class 
was defined based on people occupation and registrar five social classes which people in 
the highest social class will be considered as class I. They found that there was inverse 
relationship between level of education of women and risk of developing Metabolic 
Syndrome. (0-4 years of education: OR= 2.28; CI: 1.48-3.51, 5–11 years of education: 
OR=1.49; CI: 0.93-2.36). Also, there was an inverse relationship between social class 
(social class I has been considered as a reference category) and risk of development of 
the Metabolic Syndrome (social class III (OR=1.85; CI: 0.89-3.85), IV (OR=2.56; CI: 
1.45-5.72), and V (OR=2.13; CI: 0.97-4.70).  In men, the magnitude of association was 
similar to women, but the association was not significant. They also concluded that social 
and economic situation had more effect on women than on men in developing Metabolic 
Syndrome (77). 
 
Loucks et al obtained data from the Third National Health and Nutrition Examination 
Survey to investigate the association between socioeconomic status and Metabolic 
Syndrome in American adults. Socioeconomic status was determined by total years of 
education and poverty income ratio (PIR which is calculating by dividing the midpoint of 
family income category to the official poverty threshold which is published by USA 
census). Odds of developing the Metabolic Syndrome  were higher for individuals with 
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less than 12 years of education than for individuals with more than 12 years education 
(men: OR= 1.27; CI: 0.97-1.66, women: OR=1.77; CI: 1.39-2.24). They also reported 
that women in the low PIR group (≤1) had a higher risk of developing the syndrome than 
women in the high PIR group (>3) (OR: 1.98; CI: 1.50-2.62), but this association was not 
significant in men (OR= 0.98; CI: 0.74-1.29). As explained by the researchers, 
socioeconomic status had a greater influence in women than men with respect to 
development of the Metabolic Syndrome (78).  
 
Dallongeville et al conducted a study among (1695 French men, 1644 French women) to 
investigate the association between household income and the Metabolic Syndrome, as 
defined by the ATP III criteria. They reported that education level was inversely 
associated with developing the Metabolic Syndrome in both men and women. Household 
income and Metabolic Syndrome were inversely associated in women, but not in men. 
They also believed that the association between socioeconomic status and the Metabolic 
Syndrome had a sex-pattern (80). 
 
Brunner et al recruited data from the Whitehall II study phase three. Their study included 
4978 British men and 2035 British women aged 39-63 years, and applied the ATP III 
criteria to define the syndrome. Six employment grades, as indicators of socioeconomic 
status, were defined based on annual salary. Grade 1 (£ 28904-87620), grade 2 (£ s 25 
330-36 019), grade 3 is Senior Executive Officer (£ 18 082-25 554), grade 4 is Higher 
Executive Officer (£ 14 456-20 850), grade 5 Executive Officer (£ 8517- 16,668) and 
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grade 6 Clerical and Office Support staff (£ 6483- 11 917). There was an inverse 
association between the employment grade and the Metabolic Syndrome (73).   
 
In another study among healthy Swedish women aged 30-65 years, Wamala et al 
examined the association between level of education and the Metabolic Syndrome. The 
ATP III definition was used. Education level was divided into three categories; low 
education (≤ 9 years), middle level of education (10-13 years), and high level of 
education (≥14 years). Their results showed that women in the lowest education category 
had greater odds of having the syndrome than women in the highest group (OR=2.34; CI: 
0.98-5.84).  Also, results showed that women with middle education level had lower risk 
of development of Metabolic Syndrome  than women in the highest group , but the 
association was not significant (OR=1.27; CI: 0.39-4.14) (65). 
 
Silventoinen et al conducted a longitudinal study among middle aged (45-65) Finnish 
men (864) and women (1045) without a history of coronary heart disease. The study used 
the ATPIII and the WHO definitions to define the Metabolic Syndrome. They followed 
up participants to investigate whether they develop CHD events over ten years, and 
considered death or hospitalization due to CHD as outcome variables. They observed that 
there was an inverse association between education level and Metabolic Syndrome. Their 
results also showed that there was an educational gradient in development of CHD events 
after the adjustment for the Metabolic Syndrome in their analysis (HR=0.73; CI: 0.52-
1.04) (79). 
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Park et al obtained the data (men=3657, women=4884) from the Korean National Health 
and Nutrition Examination Survey (2001) to examine the association between education 
or income level and the Metabolic Syndrome. The inverse relationship found between 
education (7-9 years, 10-12 years, and >12 years), income level (low, middle, high), and 
Metabolic Syndrome was only significant in women, not in men (59). 
 
 Park et al in a study of American adults, as discussed earlier, considered education level 
and income level as measure of socioeconomic status. They found that women with 
household incomes of less than $15000(low income) had higher odds of developing 
Metabolic Syndrome (OR=1.5; CI: 1.0-2.3) than women with household income greater 
than $25000(high income).  They did not find any significant association between level 
of education and the Metabolic Syndrome in either sexes (48).  
 
Park et al in a cross-sectional study among Korean adults, as explained previously, found 
that there was no association between income or education level and Metabolic 
Syndrome in both sexes (49). 
 
VII. EMPLOYMENT  
A few studies evaluated the association between Metabolic Syndrome and employment 
status. There is a debate regarding the association of these two variables. Most studies 
agree that employment is a protective factor (49,77), but a few studies reported that it was 
a risk factor (table 14) (82). 
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Table 14. Association between Metabolic Syndrome and employment status 
Author  Definition 
of MetS  
used   
Sample population Study design  Association with 
employment status 
Park, H.S. 
et al 
(2004) 
ATP III Korean men (n=3937) 
Korean women (n=4713) 
Cross-sectional Unemployment:  
Men  
OR= 2.0(1.4-2.8) 
Women  
OR=1.7(1.0-2.7)  
 
Ana, S et 
al (2008) 
ATP III  Portuguese women (n=1332) 
Portuguese men (n=832) 
Nutrition  survey 
/Cross-sectional 
Women: 
Retirement   
OR=1.48(0.96-2.27) 
Housewife:  
OR=1.77(1.16-.7) 
 
Lucove, 
J.C et al 
(2007) 
ATP III African Americans (n= 1006) Longitudinal Employment 
Men:  
OR= 0.48(0.12-1.87) 
Women: 
OR= 1.52(1.04-2.21) 
 
Park et al in a cross-sectional study among Korean adults found that unemployed 
individuals had a higher risk of developing Metabolic Syndrome than employed 
individuals; men (OR= 2.0; CI: 1.4-2.8) and women (OR=1.7; CI: 1.0-2.7) (49). Santos et 
al also found that being retired (OR=1.48; CI: 0.96-2.27) or a housewife (OR=1.77; CI: 
1.16-.7) were risk factors for developing the Metabolic Syndrome in women.  In men, 
although the odds of developing Metabolic Syndrome for retirees or homemakers were 
higher, their association was not significant (77).  
 
Lucove et al obtained data from the Pitt County Study, a prospective study, started in 
1988 with two follow up visits (1993 and 2001), to investigate the risk factors for the 
development hypertension . They obtained information about the components of 
Metabolic Syndrome and employment status of participants in their first visit. 
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Participants with normal blood pressure were invited for the first follow up visit. Their 
results showed that being employed was a risk factor for developing the Metabolic 
Syndrome (OR= 1.52; CI: 1.04-2.21) in women, and a protective factor in men (OR= 
0.48; CI: 0.12-1.87) (82).  
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1.8. Metabolic Syndrome and cardiovascular disease 
The association between the components of Metabolic Syndrome and cardiovascular 
disease incidence and mortality has been shown in several studies (83-86). 
Also, several studies showed that the risk of developing cardiovascular events was higher 
in people with the Metabolic Syndrome than those without the syndrome (21,22,87,88). 
As explained earlier, the prevalence of the syndrome varies based on the definitions of 
the Metabolic Syndrome used, and there is dilemma regarding which definitions should 
be used in clinical practice and research (12). The main purpose of the definitions is to 
identify individuals who have a higher risk for developing CVD and diabetes. Thus, one 
of the best ways to answer these questions would be comparing the definitions regarding 
their predictive accuracy of CVD events and mortality. Several studies compared CVD 
mortality and all cause mortality by applying different definitions. Yet these studies 
varied as to the baseline population, the number of deaths, modification of the definitions 
and adjustment for different potential confounders in the analyses. Thus, these issues 
make the comparison of studies difficult (89). 
 
Ford et al in a meta-analysis searched the PubMed database from 1998 to 2005 to find 
studies which examined the association between Metabolic Syndrome and cardiovascular 
disease. To be included, studies needed to be prospective, and used the WHO, the 
ATPIII, or modified definitions. Twenty one studies were included; follow up years 
ranged from 3 to 13.5 years. Covariates considered as potential confounders were varied 
in different studies. The population-attributable fraction for cardiovascular events for 
subjects with Metabolic Syndrome was calculated by Ford et al. In the formula the 
 53 
prevalence of the syndrome was considered 21.8% and relative risk was obtained from 
the meta-analysis. Risk of developing of cardiovascular events was higher for individuals 
with the syndrome than those without the syndrome when the precise definitions of 
Metabolic Syndrome were applied. (ATP III RR=1.65; CI: 1.38-1.99, WHO RR=1.93; 
CI: 1.39-2.67). Also, similar results were found when the studies which used the exact or 
modified definition were pooled together (ATP III RR=1.74; CI: 1.43-2.12, WHO 
RR=2.06; CI: 1.72-2.47). RR was higher in those studies which included individuals with 
diabetes (2.2) than those studies which did not include individuals with diabetes (1.58). 
The population-attributable fraction was 12% and 17% when the ATP and the WHO 
definition were applied, respectively (87).  
 
Galassi et al, in another a meta-analysis, searched the MEDLINE data base from 1966 to 
2005 to find studies which investigated the association between the Metabolic Syndrome 
and risk of cardiovascular disease. They included those studies which had prospective 
design and applied the WHO, the ATP, or modified definitions. Among eligible studies, 
only those studies were included in which the end points were non-fatal cardiovascular 
events, cardiovascular mortality, or all cause mortality, and those which calculated 
relative risk (RR), hazard ratio, or odds ratio. Twenty one studies, 11 in the US and 10 in 
Europe, met the inclusion criteria. Sixteen, five, and two studies used the ATP, the WHO, 
and both definitions, respectively. The range of follow- up period was between 2.8 years 
and 13.5 years.  Cardiovascular disease mortality was reported to be higher in individuals 
with the Metabolic Syndrome than those without the syndrome (men RR=1.5; CI: 1.41-
1.75, women RR=2.1; CI: 1.79-2.45). The pooled RR was higher for studies applying the 
 54 
WHO as opposed the ATP definition (WHO RR=1.82; CI: 1.27-2.61, ATP III RR=1.61; 
CI: 1.42-1.83) (21). 
 
One year later, Gami et al conducted another meta-analysis with a more comprehensive 
search. They searched MEDLINE (from 1966 till 2005), Ovid EMBASE (from 1988 till 
2005), Web of Science (from 1993 till 2005), abstracts were presented in scientific 
sessions in 2003 and 2004, and studies were that referenced Reaven’s article. The 
following studies were included: cohort studies or randomized trials, studies that reported 
risk estimates or its synonym, and studies that reported non-fatal cardiovascular events or 
CVD mortality. Follow-up times ranged from 2.2 to 18.8 years. Thirty seven studies met 
the inclusion criteria. Six studies used the WHO, twelve the ATP III, four modified 
WHO, and ten modified ATP definitions. 5 studies used factor analysis, which means to 
create a variable which was nearly similar to the components of the Metabolic Syndrome 
in the WHO or ATP definitions. The results showed that individuals with Metabolic 
Syndrome had a higher risk of non-fatal cardiovascular events or CVD death than those 
without the syndrome (RR=1.78; CI; 1.58-2.00). Seven studies estimated the RR for both 
sexes; the risk of cardiovascular events was higher in women than men in those studies 
(RR 2.63 VS 1.89; p=0.09). Their results also showed that the WHO definition predicts 
cardiovascular events better than the ATP III definition (RR 2.68 vs 1.35; p=0.005) (22). 
 
Qiao et al analyzed data from the DECODE study. The DECODE study included nine 
European population based cohort studies which primarily examined the prevalence of 
diabetes in European adults.  Studies were started around 1990, and the follow-up was 
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between 6.6 to 16 years. Qiao et al studied 4715 men and 5554 women, aged 30-89 years. 
They used the ATP, IDF, and the WHO definitions of Metabolic Syndrome. They found 
that CVD mortality was higher for individuals with Metabolic Syndrome than without the 
syndrome for both sexes regardless of the definition. Hazard Ratio for CVD mortality in 
men were 2.09 (CI: 1.59-2.76), 1.74 (CI: 1.31-2.30), and 1.51(CI: 1.15-1.99) according to 
the WHO, the ATP, and the IDF definitions, respectively. The comparable numbers in 
women were 1.60(CI: 1.01-2.51), 1.39(CI: 0.89-2.18), and 1.53 (CI: 0.99-2.36). They 
conclude that all definitions can predict the CVD mortality, but the association was 
weaker in women regardless of definition (90). 
 
Katzmarzyk et al studied 20789 men aged 20-83 years from Aerobics Center 
Longitudinal Study in the USA. They examined the association between the Metabolic 
Syndrome and CVD mortality and all cause mortality by using ATP III (2001 and 2005) 
and the IDF definitions. The results showed that RR for CVD mortality was 1.79(1.35-
2.37), 1.67(1.27-2.19), and 1.67(1.27-2.20) according to the ATP III 2001, ATP III 2005, 
and IDF definitions, respectively.  As shown in the results, the ability of the IDF and 
ATP III to predict mortality was almost the same (40). 
 
Nilsson et al used that data from the Malmo Diet and Cancer study. The study was started 
in 1992, and participants were followed until 2003. The primary purpose of the study was 
to examine which definition of Metabolic Syndrome  will best predict cardiovascular 
events, which has been defined as  fatal or non-fatal myocardial infarction (MI; ICD-9 
code 410), fatal or non-fatal stroke (ICD-9 codes 430, 431, 434, 436), or death due to  
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ischemic heart disease (ICD 410–414).  They recruited 3382 non-diabetic women and 
1665 non-diabetic men. They defined the syndrome by the ATP III, the IDF, and the 
EGIR definitions. The prevalence of the syndrome was higher by the IDF definition than 
the ATP III definition in both men and women after adjusting for age, sex, LDL, 
smoking, alcohol intake, level of education and physical activity. Adjusted Hazard ratios 
for CVD events in men according to the ATP, the EGIR, and the IDF definitions were 
1.71(CI: 1.26-2.31), 1.33(CI: 0.97-1.82), and 1.17 (CI: 0.85-1.60), respectively. The 
corresponding numbers in women were 1.45(CI: 0.97-2.17), 1.42 (CI: 0.92-2.18), and 
1.05(0.68-1.62). As a result, they concluded the IDF definition was not better than other 
definitions at predicting CVD events (91). 
 
Wang et al conducted a cohort study between 1988 and 2001 to examine the relationship 
between the Metabolic Syndrome  and CVD (ICD-9 codes 390 to 459), CHD (ICD-9 
codes 410 to 414), and all-cause mortality among non-diabetic Finnish people (377 men, 
648 women) aged 65-74. The syndrome was defined by the WHO, the APT III (2001 
AND 2005), the IDF, and the ACCE definitions. In men, the syndrome predicts the CVD 
mortality by WHO, the ACCE definitions, both versions of ATP III definitions 
(borderline significant).  However, in women, none of the definitions predicted CVD 
mortality. Hazard ratios for CVD mortality in men  were 1.43( CI:1.00-2.03), 1.32 
(CI:0.93-1.98),and 1.34( CI:0.94-1.92), and 1.27(CI:0.89-1.82), 1.29(CI:0.89-1.87),and 
1.32(CI:0.90-1.94) in women, according to the ATP III (2001), ATP III (2005), and the 
IDF definitions, respectively (89).  
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Benetos et al studied French men (55794) and women (28963). Participants had no CVD 
at the baseline of study and were followed for five years. At the end of the study period 
cause of death were obtained from death certificates. The syndrome was defined by the 
ATP III (2001 and 2005) and the IDF definitions. Hazards of CVD mortality were 
2.05(1.28-3.28), 1.64(1.08-2.05), and 1.77(1.18-2.64) according to the ATP III (2001), 
ATP III (2005), and the IDF definitions, respectively (92). 
 
Choi et al used the data from the 2001 Korean Nation Health and Nutrition Survey, which 
was nationally representative of the Korean population, to compare the association 
between the Metabolic Syndrome and cardiovascular disease. Men (2583) and women 
(3381), 20 years and older were included in this study and the Metabolic Syndrome was 
defined by the ATP III and the IDF definitions. The results showed that the prevalence of 
the Metabolic Syndrome  was higher according to the IDF definition (23.9 %) than the 
ATP III definition (20.5%), while it was reversed in men (IDF:15%, ATP III 17.8%). 
Also, the odd of developing coronary artery disease were 2.3 (CI: 1.2-4.3) and 1.5 (0.8-
2.7) by the ATP III and the IDF definitions, respectively (93).  
 
Koutsovasilis et al conducted a cross-sectional study among 211 patients who were 
admitted to hospital for the first time for acute coronary syndrome (ACS) between 2006 
an 2007. A control group of 210 individuals who had chest paint with no cardiac origin 
was included in this study.  They used the ATP (2001 and 2005) and the IDF definitions 
to define the syndrome. The corresponding prevalence of the Metabolic Syndrome among 
patients with ACS were 72.5%, 81.2%, and 79.1%. The significant association between 
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the Metabolic Syndrome and developing the ACS was only observed when the IDF 
definition applied (IDF OR=2.23; CI: 1.30-3.82, ATP III- 2001 OR=1.13; CI: 0.63-2.00, 
ATP III-2005 OR=1.42; CI: 0.79-2.56) (94).   
 
1.9. Metabolic Syndrome versus other assessment tools  
There is a debate regarding the ability of Metabolic Syndrome to predict CVD events in 
comparison with other assessment tools such as Framingham Risk Score (FRS) (32). 
Some studies suggested that the Metabolic Syndrome was inferior to the Framingham 
Risk Score (FRS) in the prediction of CVD events (95-97). However, other studies 
agreed that the syndrome was a superior predictor of CVD than the FRS (98,99). 
 
McNeil et al conducted a longitudinal study, between 1987 and 1989, to examine the 
association between the Metabolic Syndrome and cardiovascular events. The ATP III 
definition was used. 12089 black and white Americans men and women aged 45-64 who 
lived in North Carolina, Mississippi, Minnesota, and Maryland were included in the 
study. They calculated the Framingham Risk Scores for the participants and divided the 
scores into two categories (<10% and ≥10%).  They also generated the receiver operating 
characteristics (ROC) curves to examine whether Metabolic Syndrome can predict the 
CHD better than the FRS. The results showed that hazard ratios for developing CHD 
were higher in subjects with Metabolic Syndrome than those without the syndrome (men 
HR=1.46; CI: 1.23-1.74, women HR=2.05; CI: 1.59-2.64). Also the results showed that  
individuals with the Metabolic Syndrome within lower strata (FRSs<10%) 
had a higher incidence of CHD than those without the syndrome within the same strata. 
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(men 90.3 vs 65.4, women 52.2 vs 21.8). The similar results were also found for 
individuals at higher strata, FRSs≥10%.  (men 164.6 vs 133.8, women not estimable in 
women). According to the ROC curves, they explained the Metabolic Syndrome did not 
predict CHD events better than the FRS (men 0.631 vs 0.634, women 0.729 vs 0.731). 
However, they explained that individuals who had Metabolic Syndrome had higher risk 
of developing CHD than those without the syndrome within the same the FRSs category. 
They explained that, by using the FRS clinicians can identify individuals who are at the 
later stage of development of CVD events, while by identifying individuals with the 
syndrome clinicians can identify individuals who are at the earlier stage (95).  
 
Another prospective study was conducted between 1979 and 2000 by Wannamethee et al 
to compare the Metabolic Syndrome and the FRS regarding their ability in prediction of 
CHD, stroke, and diabetes. 5128 British men without history of CHD, stroke and diabetes 
from 24 towns in England, Wales, and Scotland were included in the study. They used 
the ATP III definition. The results showed that individuals with the Metabolic Syndrome 
had a higher risk of developing CHD, stroke and diabetes than those without the 
syndrome. According to the ROC curves the FRS was a better predictor than the 
Metabolic Syndrome for CHD (68% vs 59 %), while the syndrome was a better predictor 
for diabetes than the FRS (70% vs 60%). They also concluded that even though the 
syndrome was not a better predictor for CHD events, it could be considered as a tool 
which can identify individuals who were at the risk of development of CHD (96).  
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Stern et al obtained the data from the San Antonio Heart Study to investigate whether the 
Metabolic Syndrome had a better predict ability in prediction of diabetes and CVD events 
than the FRS. The ATP III definition was applied in the study. 1079 individuals without 
diabetes and CVD were followed for eight years. The results showed that the Metabolic 
Syndrome could predict the CVD with a sensitivity and false positive rate of 67.3% and 
34.2%, respectively. However, they fixed the false-positive rate at 34.2 % to calculate 
sensitivity for the FRS, and found a higher value (81.4%). They also fixed the sensitivity 
at the 67.3% and calculated the false positive ratio for the FRS, and found a lower value 
(20.0).They suggested that the Metabolic Syndrome could not provide any additional 
information regarding the prediction of CVD events compared to the FRS (97). 
 
Girman et al in obtained data from the Scandinavian Simvastatin Survival Study (4S) and 
the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 
These studies were double blind clinical trail in patients with hypercholestromia and 
primarily were designed to investigate the effect of simvastatin on mortality and 
morbidity. Girman et al recruited data from the placebo groups of both studies (4S: 2223, 
AFCAPS/TexCAPS: 3301).  The ATP III definition was used. They calculate the FRSs, 
in both studies, for having the cardiovascular events and classified the participants into 
two groups (FRS≤ 20%, FRS>20%). The cardiovascular events were higher in subjects 
with the syndrome than subjects without the syndrome in both studies (4S HR=1.46; CI: 
1.20-1.79, AFCAPS/TexCAPS HR=1.40; CI: 1.04-1.89). The results demonstrated that 
individuals who had the Metabolic Syndrome within each categories (FRS≤ 20% or 
FRS>20%) had higher risk of developing the cardiovascular events than those without 
 61 
the syndrome within the same category. They also reported that the Metabolic Syndrome 
could improve the prediction of the CVD events compared to FRS alone (99). 
 
Dekker et al obtained the data from the Hoorn study, which was a Dutch cohort study 
which started in 1989 and ended in 2000. 615 men and 749 women without diabetes and 
CVD were included in this study. The ATP III, the WHO, the IDF, and the EGIR 
definitions were used, and the FRSs were calculated. The hazard ratio for developing 
nonfatal CVD were significantly higher in men with the syndrome according to the ATP 
III and the WHO definitions compared with those without syndrome after adjustment for 
the FRS (ATP HR= 1.64; CI: 1.11–2.44,  WHO HR= 1.44; CI: 1.01–2.04, EGIR   HR= 
1.48;  CI: 0.99–2.19,  ACE  HR= 1.06; CI: 0.74–1.53)  . Regardless of definitions, after 
adjustment for the FRS, the hazard ratios of risk of nonfatal CVD were higher in women 
with the syndrome than those without the syndrome, but these associations were not 
significant (ATP HR= 1.17; CI: 0.73–1.87, WHO HR= 1.31; CI: 0.85–2.02, EGIR   HR= 
1.21; CI: 0.75–1.95, ACE HR= 1.31; CI: 0.81–2.10) (98).  
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2. Research Objectives 
As we discussed, there is limited information available about the prevalence of Metabolic 
Syndrome, its trend over time and its predisposing risk factors in Canadian adults.  No 
study has compared the prevalence of Metabolic Syndrome and its associated risk factors 
according to different definitions (NCEP and IDF) in Canada. Most studies examined the 
association between Metabolic Syndrome and all-causes mortality among non-Canadian 
population.  To our knowledge, no studies have compared the ability of NCEP and IDF to 
predict CVD mortality among Canadian adults.  This thesis will determine the prevalence 
of Metabolic Syndrome in 1986-1995 by using different definitions to establish the base 
line for future research, investigate metabolic associated risk factors, and examine the 
relation between Metabolic Syndrome and CVD mortality in Canadian adults.  
 
 
Objective 1: To examine the age and sex specific prevalence of the Metabolic Syndrome  
in Canadian adults by using the National Cholesterol Education Program and 
International Diabetes Federation definitions. 
a) To examine the prevalence of the single components of the Metabolic Syndrome 
definition and their relationship to defined Metabolic Syndrome. 
 
Objective 2: To examine the risk factors for Metabolic Syndrome in Canadian adults by 
using the National Cholesterol Education Program and International Diabetes Federation 
definitions. 
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Objective 3: To examine the association between Metabolic Syndrome and 
cardiovascular disease mortality in Canadian adults by using two definitions, National 
Cholesterol Education Program and International Diabetes Federation. 
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Abstract 
Title: The Effect of Definition on the Prevalence of Metabolic Syndrome and its 
Components.  
Background: No studies have compared the prevalence of Metabolic Syndrome (MetS) 
among Canadian adults using the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP III) and the International Diabetes Federation (IDF) definitions. 
Objective: The purpose of this study was to examine the sex specific prevalence of MetS 
 in Canadian adults by using ATP III and IDF definitions, to establish a base line for 
future research, and to determine the effect of definition on the prevalence of the 
component factors.  
Methods: The Canadian Heart Health Survey was a cross-sectional probability sample 
survey of 23179 adults ages 18-74, conducted in all 10 Canadian provinces between 1986 
and 1992 .The present study was based on 4724 men and 4712 women for whom full 
anthropometric measurements were obtained (provinces of Alberta, Manitoba, Ontario, 
Quebec and Saskatchewan) and for whom data on all components of MetS 
 were available. MetS was defined according to ATP III and IDF definitions. A weighted 
analysis using SPSS PASW Complex Samples (version18) was conducted.    
Results: According to ATP III, 17.9% and 15.3% of men and women have MetS, while 
according to IDF, 23.8% and 17.3% of men and women have MetS, respectively. Kappa 
agreement between the definitions was 72 % for men and 80% for women (p≤0.05). In 
men who have MetS according to IDF 68.3%, 86.8%, 78.3%, and 15.4% have low high-
density cholesterol, high triglyceride, hypertension, and diabetes,  respectively, versus 
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79.9%, 93.1%, 87.3%, 17.7% according to ATP III ( p≤0.001).  In women, the 
comparable levels of prevalence are 78.8%, 77.6%, 76.2%, 15.3% according to IDF, and 
83.3%, 79.2%, 82.6%, 20.5% according to ATP III (p≤ 0.001).   
Conclusion:  In Canadian adults the prevalence of MetS is higher when the IDF 
definition is applied but the metabolic derangement of individuals identified is less 
severe.  This may have implications for the prognostic value of the two definitions. 
Key words: Metabolic Syndrome, insulin resistance syndrome, insulin resistance, 
definition. 
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1. Introduction 
The Metabolic Syndrome has been known under different names, such as "syndrome X”, 
“the insulin resistance syndrome”, and the “deadly quartet (1-3). 
This concept was introduced by Kylin for the first time in 1920 as a clustering of some 
risk factors which include hypertension, hyperglycemia, and gout. Some years later, 
Vague explained that there is an association between upper body adiposity and the 
development of some metabolic abnormalities in people with cardiovascular disease and 
diabetes.  The clinical importance of Metabolic Syndrome was described by Reaven in 
1988 which explained Metabolic Syndrome as a cluster of insulin resistance, 
hyperglycemia, hypertension, low HDL-cholesterol, and raised VLDL-triglycerides (1-6). 
After this concept had been accepted by researchers and clinicians, different scientific 
organizations developed various definitions to standardize investigation of this syndrome. 
The essential components of their definitions include glucose intolerance, obesity, 
hypertension, and dyslipidemia (1,2,7,8). 
The World Health Organization (WHO) published the first definition in 1999 (2,7,9). 
After that the European Group for the study Insulin Resistance (EGIR) modified the 
WHO definition (1,2,7,10). In 2001, the U.S.A National Cholesterol Education Program 
developed the ATP III definition, which later was modified by the American College of 
Endocrinology (AACE) (1,2,7). In 2005, the National Cholesterol Education Program 
modified their first definition and the International Diabetes Federation (IDF) developed 
a new definition (8). In 2009, IDF and National Cholesterol Education Program groups 
attempted to unify these criteria (11).  
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It has been shown by several studies that the risk of developing Cardiovascular disease 
and diabetes is higher among people with MetS compared to people without MetS (4,12-
15). It has been recommended by the American Heart Association and the International 
Diabetes Federation that individuals with MetS should undergo CVD risk assessment and 
also receive ongoing follow-up. Thus identifying people with MetS has undeniable 
impact on both patients and public health care system (3,16,17).   
Several studies compared differences in prevalence of depending on definitions, but there 
is a debate regarding the choice of definition, which definition identifies individuals with 
more adverse metabolic profiles, which is more suitable for clinical practice, and which 
better predicts future CVD events (3,17-24). According to Cameron et al noted the 
prevalence of MetS varied considerably in different studies because of different study 
designs, study population, and definitions of the Metabolic Syndrome (1,7) . It would 
therefore be very important to develop a widely accepted, unified definition of this 
important syndrome (3,11,25). 
Although several studies have been done to estimate the prevalence of MetS in Europe 
and USA, little is known about the prevalence of MetS in the Canadian population. Arden 
et al (26), in a population study of 7981 Canadians, reported that the prevalence of 
Metabolic Syndrome  according to the ATP III definition was 17 % in men and 13.2 % in 
women between 1986 and 1992 (26). In another study conducted between 1986 and 1992 
among 12881 Canadians aged between 18-64 that was, Brien et al reported that the 
prevalence of Metabolic Syndrome  according to the ATP III definition was 17.5% and 
11.2 in men and women, respectively (27). Riediger et al  in a cross sectional study which 
was conducted between 2007 and 2009,  first cycle of Canadian Health Measures Survey,  
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reported that prevalence of Mets was 15.9 in Canadian men and 19.5 in Canadian women 
according to the ATP III definition (28). Although several studies compared the 
prevalence of MetS according to different definitions, and degree of concordance 
between different definitions in the European and American population, to our 
knowledge no study has compared the prevalence of Metabolic Syndrome by the ATP III 
and the IDF definition nor investigated the degree of agreement between these two 
definitions in Canada. Liu et al (29)compared the prevalence of Metabolic Syndrome  
among three ethnic groups in Canada and found a moderate agreement between the ATP 
III and  the WHO definitions (kappa agreement= 0.63) (3,29).Therefore, the purpose of 
this study was to examine the sex specific prevalence of MetS in Canadian adults by 
using the ATP III and the IDF definitions and to determine the effect of definition on the 
prevalence of the component factors and to assess the concordance between these 
definitions.  Although the prevalence of Mets in Canadian population has been reported 
recently by Riediger et al, there is lack of base line information in Canada. Thus, the 
present study will provide the base line base line information which can be used for 
future research examining trends in this syndrome over time. 
  
2. Methods 
The Canadian Heart Heath Survey (CHHS) was conducted between 1986 and 1992 in 10 
provinces among non-institutionalized Canadian men and women aged 18 to 74 years. A 
full description of the method is presented elsewhere (30). The CHHS was conducted in 
two stages (home interview and clinic visit). In brief, individuals had been invited for 
interview by using health insurance registration files. In the CHHS, 76% and 69% of 
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participants completed interview and clinic visit, respectively. During the first stage of 
data collection, participants were visited in their home by trained study nurses who 
collected basic demographic data, information about CVD risk factors, and attitudes and 
opinions about heart health related issues. They took two measurements of blood pressure 
during the home interview (one at the beginning of the session, another one at the end of 
session).  The second stage of data collection was conducted two weeks later. At this 
stage, participants visited a clinic where trained study nurses took two measurements of 
blood pressure again, performed the anthropometric measurements, and took fasting 
blood samples to determine the plasma lipid levels among the participants. During the 
data processing stage the mean of the four measurements of blood pressure was 
calculated.  
Weight and height were measured in all provinces, whereas waist circumference (WC) 
was measured in only five provinces (Alberta, Manitoba, Ontario, Quebec and 
Saskatchewan). The present study was based on 4724 men and 4712 women for whom 
full anthropometric measurements were obtained and for whom data on all components 
of MetS were available out of a total of 5916 (80%) men and 6136 (77%) women in these 
provinces. Participants were asked to dress in indoor clothing without shoes to perform 
the anthropometric measurements. Their height was measured to the nearest centimeter 
while they were standing on a hard surface against a wall. Their weight was measured to 
the nearest 100g by using a calibrated balance beam scale. During the data processing 
stage the BMI was calculated by using the standard formula (weight in kg/height in m2). 
To measure WC, trained study nurses followed the standard protocol by positioning of 
measuring tape at the level of narrowing waist circumference at the end of normal 
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expiration, or at the level of the floating rib if measuring the narrowing level of WC was 
difficult to obtain (30).  
Participants had been asked to fast for 12 hours, and subsequently the lipid profile that 
included low density lipoprotein cholesterol (LDL), high density lipoprotein (HDL), and 
Triglycerides (TG) was measured. All lipid analyses were performed at the Lipid 
Research Laboratory at the University of Toronto.  
Individuals were considered to be diabetic if they had ever been told by a physician that 
they had diabetes, although sufficient information was not available to distinguish 
between Type I and type II diabetes. Metabolic Syndrome was defined using a 
modification of the criteria from the ATP III (31) and IDF definitions (Tables 1a, 1b) (2).   
No information was available about the ethnicity of participants, thus the ethnic-specific 
cutoff point for central obesity was not applied. However, the European cutoff point was 
applied to define the central obesity because according to Statistic Canada more than 85 
% of Canadian populations were Caucasian in 1991. Also, sufficient information was not 
available about lipid lowering drugs, so individuals with normal lipid profile who were 
under treatment for dyslipidemia were not were not included in the study. 
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Table 1a. ATP III definition of Metabolic Syndrome  
Metabolic Syndrome :  
At least three of the following:  
 
 Central obesity( waist circumference ≥ 102cm for men and ≥ 88 cm for women) 
 Triglyceride ≥ 1.7 mmol/L 
 HDL< 1.03 mmol/L(men) ; HDL<1.3 mmol/L(women) 
 Blood pressure ≥ 130/85mmHg; or Drug treatment for hypertension 
 Physician diagnosis of diabetes 
* adapted from ATP III definition (Grundy 2005) 
 
 
Table 1b. IDF Definition of Metabolic Syndrome  
Metabolic Syndrome :  
 
Central obesity (defined as waist circumference exceeding specific values)*   
Plus any two of the following four factors: 
Raised triglycerides:  ≥150 mg/dL (1.7 mmol/L)  
Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in men < 50 mg/dL 
(1.30mmol/L) in women  
Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
 Physician diagnosis of diabetes 
 
*Ethnicity-specific values were not available; European cutoff point was applied:  
  Men WC≥94; Women WC≥80 
* adapted from IDF definition (Zimmet 2005) 
 
3. Statistical analysis 
The CHHS was based on a complex survey design, so standard statistical software that 
assumes the data arises from simple random sampling could not be used. All analyses in 
this study were conducted by SPSS PASW Complex Samples (version18) that took full 
account of the complex nature of the study design. A weighted analys is was performed to 
produce nationally representative and unbiased estimates. Separate models were 
examined for males and females. Kappa agreement was also calculated to analyze the 
concordance between the two definitions based on unweighted numbers. The Kappa 
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index was considered excellent, good, moderate, and weak if values were greater than 
0.81, between 0.61and 0.80, between 0.41 and 0.60, and less than 0.40, respectively.  
SAS Proc Frequency was used to test the difference between proportion for each 
components involved in the definition of Mets. Specifically “The test of the 
independence of rows and columns” (chi-square) in SPSS PAWS Complex Survey 
Software was used to compare the number of components which are present based on the 
IDF and the ATP III definition. 
 
4. Results 
Table 2a, 2b illustrate the characteristics of study subjects according to both definitions. 
A total of 4724 men and 4712 women aged 18-75 were included in this study. 
Participants with MetS were older, had higher systolic and diastolic blood pressure, lower 
HDL level, higher TG level, and higher BMI than individuals without MetS. Women 
with MetS were older than men with MetS and had higher systolic blood pressure, higher 
HDL, and higher BMI, while their TG, diastolic blood pressure, and WC levels were 
lower. 
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Table 2a.  Descriptive statistics (mean± SE) for MetS-components (men) 
 MEN (MEAN±SE) MEN (MEAN±SE) 
ATP III IDF 
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
AGE 39.99±0.39 50±0.64 39.26±0.56 49.83±0.87 
Average SBP 123.65±0.38 136.43±1.21 123.05±0.48 135.16±1.21 
Average DBP 78.18±.42 85.03±0.52 77.93±0.45 84.15±0.45 
HDL 1.24±0.02 0.94±0.01 1.25±0.01 0.99±0.01 
TG 1.45±0.3 2.9±0.12 1.41±0.02 2.6±0.11 
WC 88.49±0.27 103.21±0.39 87.48±0.30 102.79±0.38 
BMI 24.92±0.11 29.31±0.27 24.65±0.11 29.12±0.35 
 
 
 
Table 2b. Descriptive statistics (mean± SE) for MetS-components (women) 
 WOMEN (MEAN±SE) WOMEN (MEAN±SE) 
ATP III IDF 
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
AGE 40.93±0.41 53.88±0.66 40.67±0.39 53.62±0.78 
Average SBP 116.29±0.79 139.09±1.88 116.09±0.79 137.44±2.00 
Average DBP 73.33±0.66 83.12±0.93 73.21±0.68 82.57±0.96 
HDL 1.50±0.02 1.13±0.01 1.50±0.02 1.16±0.01 
TG 1.19±0.01 2.38±0.05 1.17±0.01 2.34±0.05 
WC 75.85±0.54 95.81±0.73 75.47±0.56 95.32±0.76 
BMI 23.71±0.35 30.54±0.32 23.58±0.36 30.39±0.18 
 
According to ATP III, 17.9% and 15.3% of men and women have MetS, while according 
to IDF, 23.8% and 17.3% of men and women have MetS, respectively. The prevalence of 
MetS is shown in table 3 based on two definitions. Kappa agreement between the 
definitions is 72 % for men and 80% for women (p≤0.05).  
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Table3. Comparison of definitions of MetS according to ATP III and IDF by sex, 
weighted percentage agreement 
 
 
Table 4 demonstrates the prevalence of the MetS-components according to ATP III and 
IDF definitions in both sexes. As it is shown, ATP III definition identifies people with a 
more adverse metabolic profile. In men who have MetS according to IDF definition 
68.3%, 86.8%, 78.3%, and 15.4% have low high-density cholesterol, high triglyceride, 
hypertension, and diabetes,  respectively, versus 79.9%, 93.1%, 87.3%, 17.7% according 
to ATP III (p≤0.001).  In women, the comparable levels of prevalence are 78.8%, 77.6%, 
76.2%, 15.3% according to IDF, and 83.3%, 79.2%, 82.6%, 20.5% according to ATP III 
(p≤0.001).  Furthermore, if one examines the risk profile of individuals in the discordant 
cells of table 2, one observes that; in men who have been diagnosed only by IDF 50.6%, 
76.7% , 62.9%, and 9.9% have low high-density cholesterol, high triglyceride, 
hypertension, and diabetes,  respectively, versus 97.1%,99.6%,  94.1%, 13.8% according 
to only ATP III. In women, the comparable levels of prevalence are 64.5%, 79%, 53.6%, 
2.8% according to only IDF, and 89.1%, 96.1%, 87.1%, 37% according to only ATP III. 
These data show that 29.9%, 24.4%, 20.1% of men met 0, 1, 2 criteria of IDF definition, 
respectively, versus 33.6%, 27.4%, 21.1% of men met 0, 1, 2 criteria of ATP III. The data 
Definition MEN WOMEN 
ATP III ATP III 
Metabolic 
Syndrome (%) 
Normal (%) Metabolic 
Syndrome (%) 
Normal (%) 
IDF  Metabolic 
Syndrome (%) 
16.4 
 
7.1 
 
16.2 4 
Normal (%) 2.7 73.8 1.5 
 
78.2 
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also show that 42.5%, 33.7%, 4.9% of women met 0, 1, 2 criteria of IDF definition, 
respectively, versus 39.5%, 30.5%, 14.7% of ATP III (Figs 1 and 2) (p≤ 0.05). 
 
Table 4.  Prevalence of MetS-components by ATP III and IDF definitions stratified 
by sex.  
 MEN WOMEN 
IDF ATP III IDF ATP III 
 Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Low 
HDL* 
18.5% 
 
68.3% 
 
19.5% 
 
79.9% 
 
27.8% 
 
78.8% 
 
28.2% 
 
83.3% 
 
TG≥1.7 22.4% 
 
86.8% 
 
25.7% 
 
93.1% 
 
11.3% 
 
77.6% 
 
12.6% 
 
79.2% 
 
HTN** 28.8% 
 
78.3% 
 
30.4% 
 
87.3% 
 
17.5% 
 
76.2% 
 
17.7% 
 
82.6% 
 
DM 1.17% 
 
15.4% 
 
2.1% 
 
17.7% 
 
2.1% 
 
15.3% 
 
1.5% 
 
20.5% 
 
Elevated 
WC*** 
21.8% 
 
100% 
 
7.1% 
 
59.6% 
 
26.7% 
 
100% 
 
10.9% 
 
78.9% 
 
*Low HDL for men: HDL <1.03, women: HDL<1.3 
** Blood pressure ≥ 130/85mmHg or anti hypertensive treatment 
***Elevated WC by ATP III for men: WC≥102; for women WC≥88 
***Elevated WC by IDF for men: WC≥94; for women: WC≥80 
**** The difference of proportions of the two definitions is statistically significant (p ≤ 
0.001) for all components. 
 
In men, the most common combination of three criteria for MetS according to the ATP 
III definition was low HDL level, hypertriglyceridemia, and hypertension; according to 
the IDF it was hypertriglyceridemia, hypertension, elevated WC. In women, the most 
common combination of three criteria for MetS according to the ATP III definition was 
hypertension, low HDL level, and elevated WC; according to the IDF it was 
hypertriglyceridemia, low HDL level, and elevated WC.  
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Figure 1. Percentage of men meeting the specified number of criteria from the IDF 
and ATP III definitions (p≤0.05) 
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Figure 2. Percentage of women meeting the specified number of criteria from the 
IDF and ATP III definitions (p≤0.05)  
 
 
 
 
4. Discussion 
 
MetS has become a global epidemic and one the major public health concerns in the 
world. Having a unified definition which can more reproducibly identify individuals with 
MetS may improve patient care and help with public health care planning, reducing 
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overall burden (3,17). To our knowledge this study is the first attempt that compared the 
prevalence of MetS by the ATP III and the IDF definition and also investigated the 
degree of concordance between these two definitions in the Canadian population.  The 
present study will establish the base line for prevalence of MetS which can be used in 
future work.  
Over the past twenty years, regardless of the definition used by Riediger et al. (12) to 
define MetS, the prevalence has increased in Canadian women. However, the trend of the 
prevalence in Canadian men depends on the definition which is used to define MetS. The 
prevalence of MetS has decreased in Canadian men according to the ATP III (17.9 vs 
15.9).  These results should be interpreted with caution. In their study, individuals with 
WC greater than 102 (for men) and 94 (for women) are considered centrally obese, 
however, in the present study individuals with WC equal or greater than 102 (for men) 
and 94 (for women) are considered centrally obese. Also, the threshold for elevated 
fasting glucose in their study is equal or greater than 6.1, which is not the updated 
threshold (FBG≥ 5.6) which was included in the 2005 ATP III definition. These two 
factors may account for the apparent reduced prevalence of MetS in Canadian men over 
time. It is more appropriate to compare the prevalence of MetS by the ATP III definition 
in the present study with the prevalence of MetS according to the unified definition with 
high thresholds in the report by Riediger et al. (WC≥ 102 and WC≥88) as these two  
definitions of MetS are more alike. In this comparison, the prevalence of the MetS in men 
has remained essentially the same over the past twenty years (17.9 vs 17.8) (28).  
Our results show that the prevalence of MetS is higher in men than women; this finding is 
consistent with findings in some other countries such as Germany, Finland, Sweden, 
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France, and Italy. However, it is in contrast with findings in some other countries such as 
the Netherland, Greenland, Spain (25). The sex difference in Canada appears to have 
changed in recent decades. Although the present study, reporting on the 1986-95 period, 
shows a higher prevalence of MetS in men than women, Riediger et al describe a higher 
prevalence among women than men in the recent 2007-09 period. This finding may 
reflect differences in the provinces included in the two studies and/or differences in the 
statistical precision of the two estimates. In the present study, five provinces are 
considered in the analysis, while in the study by Riediger et al. all ten provinces are 
included.  As well, the larger sample size in the present study provides a narrower 
confidence interval for prevalence estimate.  Overall, these results suggest there is a need 
for public health initiatives to improve dietary habits and physical activity in Canadian 
adults, perhaps with more emphasis on women (28).  
It is well established that different MetS definitions can either overestimate or 
underestimate the prevalence of MetS (32).In this study, the results showed that the 
prevalence of MetS is higher based on the IDF definition, which is consistent with 
several other studies (16-18,22,23,25,33).  
As both definitions are based on the same components, the difference in prevalence could 
be related to 1.) the importance accorded to central obesity in the IDF definition, and/or 
2.) the use of European, not American, WC cutoff points in our use of the IDF definition 
(16).  
This study shows that the concordance between the IDF and the ATP III definition is 
good (Kappa statistics for men: 72% Kappa statistics for women: 80%) which is similar 
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with some other studies that found good concordance between these two definitions 
(20,22,25). 
In the present study, the ATP III definition identifies people with a more adverse 
metabolic profile with respect to blood pressure, LDL, and HDL. The results also show 
that individuals who have been diagnosed only with the IDF have more favorable 
metabolic profile than those who have been diagnosed only by the ATP III. These 
findings are consistent with the study by Olijhoek et al which showed that the IDF 
definition identifies patients with better cardiovascular risk profile than the ATP III 
definition (17).  Another study which was conducted by Tong et al in Chinese adults, also 
supported our results and also demonstrated that the IDF definition does not identify 
individuals who have highest risk of CHD compared to ATP III definition (34). Olijhoek 
et al (17) presented evidence that the IDF definition identifies individuals who less 
frequently have metabolic abnormalities due to insulin resistance. They propose that the 
IDF definition identifies obese individuals who have lower degree of insulin resistance or 
are have not yet developed insulin resistance. Cameron et al, in the longitudinal study 
among Australian men and women, explained this finding by stating that central obesity 
is a crucial component and is the first component that developed before others (35). Also, 
Sims el al, explained that obese individuals with a metabolically normal profile, at the 
early stage of MetS may develop symptoms of insulin resistance 10 to 20 years later (36). 
Therefore, it seems that the prognostic implication of these two definitions is unclear and 
should be subject of further research; such clarification will assist the assessment of 
clinical value of these two definitions.  
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Ardern et al in the study among the Canadian adults found that the most common 
combination of three criteria for MetS according to the ATP III was low HDL level, 
hypertriglyceridemia, and hypertension for men, and hypertriglyceridemia, low HDL 
level and high BMI for women. In the present study, in men, the most common 
combination of three criteria for MetS according to the ATP III definition was low HDL 
level, hypertriglyceridemia, and hypertension, which was the same that identified by 
Arden. When the IDF definition applied, the most combination of three criteria for men 
was hypertension, hypertriglyceridemia, and elevated WC.  In women, the most common 
combination of three criteria for MetS according to the ATP III definition was 
hypertension, low HDL level, and elevated WC, which was slightly different from the 
results that explained by Arden. When the IDF definition applied, the most common 
combination of three criteria for women was hypertriglyceridemia, low HDL level, and 
elevated WC.  McNeil et al, in a study with 12089 black and white Americans aged 45-
64, reported that among the individual components of MetS, hypertension and low HDL 
level had the strongest effects on developing the CHD risk, which was consistent with 
findings by Alexander et al among non-institutionalized American adults aged older than 
50 (37,38).Thus, as suggested by Arden et al, there should be consideration of whether 
equal weight should be given to the components of Metabolic Syndrome  to define MetS 
or  whether the criteria for MetS should be modified (39,40). 
Strengths of this study are the large sample size and a population that is representative of 
the general Canadian population. However, this study has several limitations. Firstly, the 
classification of Metabolic Syndrome relied on patient report of a physician diagnosis of 
diabetes, rather than measured fasting blood glucose. As Arden et al explained, this issue 
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can lead to underestimation of the prevalence of DM by more than 30% (41), which 
would have a marked effect on the prevalence of MetS.   
Secondly, when the IDF definition was applied, the estimation of prevalence of 
Metabolic Syndrome was based on the European waist circumference thresholds, which 
may not have been appropriate in the Canadian sample.  Unfortunately, due to the lack of 
information about the ethnicity of our population, it was not possible to choose a more 
appropriate cutoff point for central obesity, which could have lead to misclassification of 
MetS in individuals; Fortunately, according to census data by Statistic Canada, 86% of 
the population were Caucasian in 1991, so this would likely not have had a major impact. 
Thirdly, we had no information about the use of lipid lowering drugs, so individuals 
being treated for hypertriglyceridemia and who had a normal lipid profile were not 
consider as having dyslipidemia. This limitation could have lead to underestimation of 
the true prevalence of dyslipidemia and, subsequently an underestimation of prevalence 
of MetS.  
Finally, in this study we excluded individuals for whom full anthropometric 
measurements and data on all components of MetS were not available, which might have 
lead to selection bias, especially if these individuals were not representative of the overall 
group. For example, these individuals might have been unavailable to testing because 
they were less compliant or more ill. 
 
5. Conclusion  
In Canadian adults the prevalence of MS is higher when the IDF definition is applied but 
the metabolic derangement of individuals identified is less severe. The interpretation of 
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epidemiological studies would therefore be much improved by a unified and reproducible 
definition. Observing that there is an increase in the prevalence of MetS over the past 
twenty years, confirms that there is a need for public health initiative to decrease the 
prevalence of MetS in Canadian adults.   
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Abstract 
Introduction:  A modest amount is known about the prevalence of the Metabolic 
Syndrome (MetS) and its associated risk factors in Canadian adults. 
Objective:  The purpose of this study was to examine the relationship between Metabolic 
Syndrome and its associated risk factors. 
Methods:  The Canadian Heart Health Survey was a cross-sectional probability  
sample survey conducted in all 10 Canadian provinces between 1986 and 1992 .The 
present study was based on individuals for whom full anthropometric measurements were 
obtained and for whom data on all components of MetS were available (provinces of 
Alberta, Manitoba, Ontario, Quebec and Saskatchewan). MetS was defined according to 
ATP III and IDF definitions. A weighted analysis using SPSS PASW Complex Samples 
(version18) was used to conduct stepwise logistic regression analysis to identify risk 
factors significantly associated with MetS (p < 0.05). 
Results: According to ATP III, 17.9% and 15.3% of men and women have MetS, while 
according to IDF, 23.8% and 17.3% of men and women have MetS, respectively. Older 
age and low level of physical activity were significant risk factors for the MetS regardless 
of gender and definition. Higher level of education and alcohol consumption were 
additional significant protective factors for women, whereas retirement and being 
unemployed were additional significant risk factors for men. 
Conclusion: Demographic, socio economic factors, and lifestyle habits are significantly 
associated with MetS among the Canadian adults  
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1. Introduction 
The Metabolic Syndrome (MetS) is a clustering of risk factors which poses a risk for 
diabetes and cardiovascular disease. Several studies have shown that there is an 
association between the components of MetS and cardiovascular disease mortality (1-
4).Other studies have reported that cardiovascular events are higher among people with 
the MetS (5-7), therefore the identification of the risk factors of MetS is an important 
issue for both researchers and patients.  
  It has been well documented that regardless of the definitions that have been used to 
define MetS, the prevalence of MetS depends on age (8). Some studies have observed 
that the prevalence of MetS reaches its peak in the seventh decade of life and after that 
decreases (9-12). However, some studies have found that the prevalence of MetS 
continues to increase even after the seventh decade of life (8).  
The association between the individual components of Metabolic Syndrome and income 
level or educational level, which are considered as the determinants of socioeconomic 
status (SES), has been illustrated by many researchers (13). The literature has shown that 
individuals with low SES have a higher prevalence of  cardiovascular risk factors, 
including smoking, hypertension, impaired glucose tolerance, diabetes, physical 
inactivity, and obesity (13-20). Most researchers have found an inverse relationship 
between Metabolic Syndrome and socioeconomic status (14,17,21-26). However, a few 
studies have found no association between the Metabolic Syndrome and socioeconomic 
status (27).  
The association between employment status and MetS is controversial. Most research has 
shown that the risk of developing MetS is higher in unemployed than employed 
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individuals (21,28). However, Lucove et al, in a study in African American population, 
found that employed  individuals had higher risk of developing MetS than unemployed 
individuals, although this association was not statistically significant ( OR= 1.21; 95 
%CI= 0.85, 1.73) (29).  
Many studies have shown that being physically active can reduce the prevalence of 
Metabolic Syndrome  (12,24,28,30-32) because physical activity can reduce blood 
pressure, triglyceride level and abdominal obesity but increases HDL cholesterol level 
(32-35). 
There is considerable debate regarding the effect of consumption of alcohol on the 
prevalence of MetS (36). Some studies have reported that individuals with moderate 
alcohol consumption have a lower prevalence of MetS (37,38). This protective effect 
might be explained by the effect of moderate alcohol consumption in increasing HDL 
cholesterol level, decreasing blood pressure, and improving insulin sensitivity (39-44). 
However, a few studies have found a negative association (36) or no association between 
the Metabolic Syndrome and alcohol consumption (31,45). 
There is a much controversy about the association between Metabolic Syndrome and 
smoking. It has been well documented that smoking can increase blood pressure, elevate 
triglyceride level, decrease HDL- cholesterol level, and impair insulin function (28,46-
49). Thus, several studies reported that individuals who are smokers are at an increased 
risk of developing MetS (14,28,44). However, some studies have reported an inverse 
relationship between smoking and obesity (31), which could lead to a lower prevalence of 
MetS among smokers (50).  
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To our knowledge, there is little reported about the association between Metabolic 
Syndrome and marital status, although few studies have shown that the risk of developing 
MetS is higher among divorced, widowed, and unmarried women than married women 
(28,51).  
Although there is some information available about the prevalence of Metabolic 
Syndrome in the Canadian population, little is known about its predisposing risk factors 
using the ATP III and the IDF definitions (52,53). The purpose of this study was to 
examine the relationship between Metabolic Syndrome and its associated risk factors 
according to both definitions the ATP III and the IDF. 
 
2. Methods 
The Canadian Heart Heath Survey (CHHS) is a cross sectional study which was 
conducted between 1986 and 1992. Non-institutionalized Canadian men and women aged 
18-74 years were recruited from ten provinces. A full description of the recruitment 
method is presented elsewhere (54). The CHHS was conducted in two stages: a home 
interview and clinic visit.  The study population was identified by using provincial health 
insurance registration files. MacLean et al reported that 76% of participants completed 
the interview visit. During the home interview, basic demographic data, information 
about the CVD risk factors, and attitudes and opinions of participants about health-related 
issues were collected by a by trained study nurses. The nurses measured the blood 
pressure of participants at the beginning and end of the interview.  Participants completed 
clinic visits within two weeks and were in turn visited by the study nurses. . MacLean et 
al reported that 69% of participants completed the clinic visit.  At this visit, the nurses 
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measured blood pressure at the beginning and end of the session, performed the 
anthropometric measurements, and took fasting blood samples to determine the plasma 
lipid levels. The mean of four blood pressure measurements were calculated by the 
researchers during the data processing stage. Participants had fasted for 12 hours to 
measure the lipid profile, which included low density lipoprotein cholesterol (LDL), high 
density lipoprotein (HDL), and triglycerides (TG). The Lipid Research Laboratory at the 
University of Toronto conducted all lipid analysis.  
Weight and height were measured in all provinces, whereas waist and hip circumference 
were measured in only five provinces (Alberta, Manitoba, Ontario, Quebec and 
Saskatchewan). A total of 5916 men and 6136 women from these five provinces 
participated in the survey. Of these, 4724 men and 4712 women had complete 
information on anthropometric measurements and all components of Metabolic 
Syndrome. Participants wore indoor clothes while the nurses measured the 
anthropometric components. The nurses asked the participants to stand on a hard surface 
to measure the height and used a calibrated balance beam scale to measure the weight. 
During the data processing stage the BMI was calculated by using the standard formula 
(weight in kg/height in m2). The standard protocol was applied by the study nurses to 
measure waist circumference (WC). Specifically, they placed measuring tape at the 
narrowest waist circumference at the end of normal expiration, or at the level or at the 
level of the floating rib if measuring the narrowing level of WC was difficult to obtain 
(54). 
Individuals were considered to be diabetic if they had ever been told by a physician that 
they had diabetes. However, in the study there was not sufficient information available to 
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distinguish Type I and type II diabetes. Age was categorized into six categories (18- 24; 
25-34; 35-44; 45-54; 55-64; 65-74). Smoking status was categorized as never-smoker 
(participants who never smoked), current smoker (participants who smoke at least one 
cigarette every day), and former smoker (participants who had stopped smoking).   
Drinking status was categorized as never-drinker (participants who never drank), former 
drinker (participants who had stopped drinking), and current drinker (participants who 
reported alcohol drinking during the past month).  
Participants were considered physically active if they were engaged in physical activity at 
least once per week during the previous month for a duration of at least half an hour, 
otherwise they were considered as sedentary individuals.   
Income level, educational level, and employment status (which are determinants of 
socioeconomic status) were considered in the study. Three levels of income were defined 
in the study based on the ratio of household income to Statistics Canada’s income cut-
offs for different family sizes (54). One person with an income of $25000 or more, or two 
or more people with an income of $50 000 or more were considered as high income 
individuals. One person with an income between $12000 and $24999, two people with an 
income between $12 000 and $49999, or three or more people with an income between 
$25 000 and $49 999 were considered as middle income individuals. Finally, one or two 
people with an income of less than $12 000 or three or more people with an income of 
less than $25000 were considered as low income individuals (54).  The education level of 
participants was classified into elementary, some secondary, secondary and university 
degree.  To determine employment status, participants were asked “what is your current 
employment status?” Employment status was categorized into full time, part time, 
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unemployed, laid off, retired, home maker and other. Marital status was classified as 
single (which included never married, widowed, and divorced) or married (which 
included married and common-law marriage). 
Metabolic Syndrome was defined using a modification of the criteria from the  
ATP III (55) and IDF Definitions (Tables 1a, 1b) (56).  There was no information 
available about the ethnicity of participants in this study, thus the ethnic-specific cutoff 
point for central obesity was not applied. According to Statistic Canada more than 85 % 
of Canadian populations were Caucasian in 1991, so the European cutoff point was 
applied to define the central obesity. 
There was no information was available about lipid lowering drugs, so individuals who 
was under treatment for dyslipidemia with normal lipid profile were not considered to be 
dyslipidemic. Diagnosis of diabetes was based on patient reports of a physician diagnosis 
because fasting blood glucose was not measured during the data gathering phase.  
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Table 1a. ATP III definition of Metabolic Syndrome  
Metabolic Syndrome :  
At least three of the following:  
 
 Central obesity( waist circumference ≥ 102cm for men and ≥ 88 cm for women) 
 Triglyceride≥ 1.7 mmol/L 
 HDL< 1.03 mmol/L(men) ; HDL<1.3 mmol/L(women) 
 Blood pressure ≥ 130/85mmHg; or Drug treatment for hypertension 
 Physician diagnosis of diabetes 
* adapted from ATP III definition (Grundy 2005) 
 
 
Table 1b. Definition of Metabolic Syndrome according to IDF 
Metabolic Syndrome :  
Central obesity (defined as waist circumference exceeding specific values)*   
Plus at least two of the following four factors: 
Raised triglycerides:  ≥150 mg/dL (1.7 mmol/L)  
Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in men < 50 mg/dL (1.29 
mmol/L) in women 
 Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
 Physician diagnosis of diabetes 
 
*Ethnicity-specific values were not available; European cutoff point was applied:  
  Men WC≥94; Women WC≥80 
* adapted from IDF definition (Zimmet 2005) 
 
Statistical analysis 
The CHHS is a complex survey design, so standard statistical methods that assume the 
data arise from simple random sampling were not be used. Rather, analysis in our study 
was conducted by SPSS PASW Complex Samples (version18) that took full account of 
the complex nature of the study design. A weighted analysis was performed to produce 
nationally representative and unbiased estimates. Separate univariate and multivariate 
models were examined for males and females. Crude and adjusted odds ratio and 95 % 
confidence intervals were computed to estimate the degree of association between 
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Metabolic Syndrome and different risk factors. Independent variables included in the 
univariate analysis were: age, the level of education, income adequacy, employment 
status, alcohol drinking status, smoking status, and marital status. All variables which 
were significantly associated with the Metabolic Syndrome at the univariate logistic 
regression analysis (P≤ 0.25) were entered into the multivariate logistic regression 
analysis. After adjusting for relevant variables, the interaction term were examined.  
 
3. Results 
According to the ATP III definition, 17.9% of men and 15.3% of women have MetS, 
while according to the IDF definition, 23.8% of men and 17.3% of women have MetS.  
Table 2 and table 3 illustrate the characteristics of study subjects in the present study. As 
it is shown in table 3, the prevalence of MetS is higher according to the IDF definition 
than the ATP III definition. The magnitude of association between different risk factors 
and the prevalence of MetS is the same between the two definitions in both sexes. 
Compared to the ATP definition, prevalence of MetS is higher in different categories of 
different risk factors according to the IDF definition. 
Regardless of definition, in both sexes, there is an inverse relationship between the levels 
of education and income and prevalence of MetS. Prevalence of MetS is higher among 
individuals who had stopped drinking alcohol and smoking than those who were current 
smokers and alcohol drinkers. The prevalence of MetS is higher in married individuals 
than single individuals.  The prevalence of MetS is also higher among sedentary than 
active individuals.  
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The age-specific prevalence of MetS according to the two different definitions is shown 
in figures 1a and 1b. Prevalence of MetS increases with age in both sexes and according 
to both definitions, the prevalence of MetS in all age groups is higher according to the 
IDF definition compared to the ATP III definition. Compared to women, men have 
higher prevalence of MetS according to both definitions in all age groups.   
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 Figure 1a.  Age- specific prevalence of MetS by the IDF and ATP III definitions in women 
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Figure 1b.  Age- specific prevalence of MetS by the IDF and ATP III definitions in men 
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Table 2. Characteristics of study participants stratified by sex. 
 Men Women 
 % ( number) %( number) 
AGE 18-24 11.4(602) 10.9(608) 
25-34 27.4(1479) 26.1(1545) 
35-44 24.7(700) 23.1(674) 
45-54 15(444) 15.1(492) 
55-64 12.6(432) 13.5(414) 
65-74 8.8(1067) 11.3(979) 
Income level Low 10.8(602) 20(815) 
Middle 44.1(2092) 42.9(2028) 
High 45.1(1585) 37.1(1226) 
Educational level Elementary 5.8(272) 7.2(223) 
Some secondary 21.9(1300) 21.1(1201) 
Secondary 47.9(2183) 52.9(2475) 
University degree 24.3(951) 18.8(795) 
Employment status Full time 66(2822) 38.4(1608) 
Part time 7.7(350) 20.7(824) 
Unemployed 7.7(211) 3.5(131) 
Laid off  1.1(43) 0.6(27) 
Retired 11.4(978) 8.2(543) 
Home maker 0.6(27) 25.1(1334) 
Student  3.9(169) 2.2(153) 
Other 1.6(119) 1.2(90) 
Exercise 
(≥ 1 time/week) 
Yes 60.1(2936) 66.2(3088) 
No 39.9(1788) 33.8(1623) 
Alcohol Never Drinker 1.4(72) 7.3(266) 
Former drinker 8.5(482) 10.1(563) 
Current drinker 90.1(4168) 82.6(3882) 
Smoking Never smoker 32.5(1310) 45.9(1963) 
Former smoker 39.7(1908) 29.5(1426) 
Current smoker 27.8(1154) 24.6(1107) 
Marital status Single 32.1(1388) 34.7(1472) 
Married  67.9(331) 65.3(3237) 
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Table 3. Prevalence of MetsS (in terms of weighted percentages) based on the ATP 
III and IDF definitions stratified by sex and risk factors. 
 Men Women 
 %  %  
 ATP III IDF ATP III IDF 
AGE 18-24 3 3.9 2.4 3.7 
25-34 8.7 11 4.1 5.7 
35-44 17.4 23 13.4 14.1 
45-54 27.4 39.3 19.9 22.2 
55-64 29.8 41.2 28 29.1 
65-74 34.1 40.5 36.5 43.4 
Income adequacy Low 17.6 27.3 18.7 19.8 
Middle 19.7 25.5 15.5 17.5 
High 15.5 21.3 10.9 13.6 
Educational level Elementary 32.6 41.6 43 42.6 
Some secondary 24.4 29.2 24.4 25.6 
Secondary 15 22.2 11.3 14.1 
University degree 13 16.5 5.9 7.5 
Employment status Full time 16.2 22 9.6 12.4 
Part time 8.5 11.4 10.4 12.5 
Unemployed 23.1 30.3 7.1 9.2 
Laid off  13 3.6 5.3 5.7 
Retired 36.9 44.4 32.2 36.5 
Other 12.7 44 19.6 20 
Home maker 19.6 20.8 24.9 25 
Student 3.2 4.2 2.9 3.5 
Exercise 
(≥ 1 time/week) 
Yes 13.7 20.1 11.5 13.5 
No 24.2 29.4 22.8 24.7 
Alcohol Never Drinker 20 26.2 29.9 30.8 
Former drinker 26.4 35 28.6 30.3 
Current drinker 17.1 22.7 12.4 14.6 
Smoking Never smoker 12.2 15.6 15.8 16.7 
Former smoker 23.1 31.2 17.3 20.3 
Current smoker 19.9 26.7 12.2 15.4 
Marital status Single 11.4 17 15.7 16.4 
Married  21 27 15.1 17.8 
 
As summarized in table 4, age, the level of education, employment status, and physical 
activity status are significantly associated with MetS in unadjusted analysis in both sexes 
according to both definitions. Our unadjusted results also show that income adequacy is 
significantly associated with MetS according to both definitions only in women, marital 
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status and smoking status are significantly associated with MetS according to both 
definitions only in men, and alcohol drinking status is significantly associated with MetS 
only in women when IDF definition applied.  
Table 4. Univaraite odds ratios for variables associated with Metabolic Syndrome 
among men and women 
 Men Women 
 OR( 95% CI) OR( 95% CI) 
 Categories ATP III IDF ATP III IDF 
Age 18-24 Ref Ref Ref Ref 
25-34 3.1(1.6-6.2) 3.1(1.7-5.3) 1.8(0.8-3.8) 1.6(0.8-3.2) 
35-44 6.9(2.9-16.4) 7.4(3.8-14.4) 6.4(2.8-14.8) 4.3(2.3-8.1) 
45-54 12.3(5.6-26.8) 16.1(7.4-35.0) 10.3(4.0-26.6) 7.5(3.3-17.0) 
55-64 13.8(7.3-26.1) 17.4(8.7-34.9) 16.1(8.5-30.6) 10.8(6.3-18.4) 
65-74 16.8(9.0-31.5) 16.9(9.4-30.3) 23.8(11.1-51.3) 20.1(10.3-39.4) 
Income adequacy Low Ref Ref Ref Ref 
Middle 1.2(0.7-1.8) 0.9(0.7-1.3) 0.8(0.5-1.2) 0.9(0.6-1.3) 
High 0.9(0.5-1.6) 0.7(0.5-1.0) 0.5(0.4-0.8) 0.6(0.4-0.9) 
Educational level Elementary Ref Ref Ref Ref 
Some secondary 0.7(0.4-1.2) 0.6(0.4-0.9) 0.5(0.3-0.7) 0.5(0.3-0.7) 
Secondary 0.4(0.2-0.6) 0.4(0.3-0.6) 0.2(0.1-0.3) 0.2(0.1-0.4) 
University degree 0.3(0.2-0.5) 0.3(0.2-0.4) 0.1(0.0-0.2) 0.1(0.1-0.2) 
Employment status Full time Ref Ref Ref Ref 
Part time 0.5(0.3-0.9) 0.5(0.3-0.8) 1.1(0.7-1.8) 1.0(0.7-1.5) 
Unemployed 1.6(0.9-2.7) 1.5(0.8-2.8) 0.7(0.3-1.9) 0.7(0.3-1.6) 
Laid off  0.8(0.2-2.6) 0.1(0.0-0.4) 0.5(0.1-3.0) 0.4(0.1-2.1) 
Retired 3.0(2.0-4.6) 2.3(1.7-4.7) 4.5(2.9-6.9) 4.1(3.0-5.5) 
Other 0.8(0.3-2.0) 2.7(0.6-12.1) 2.3(1.1-5.0) 1.8(0.9-3.3) 
Home maker 1.3(0.3-5.1) 0.9(0.2-4.2) 3.1(2.0-4.9) 2.4(1.5-3.7) 
Student 0.2(0.3-1.1) 0.2(0.0-0.7) 0.3(0.1-1.1) 0.2(0.1-0.8) 
Exercise 
(≥ 1 time/week) 
Yes Ref Ref Ref Ref 
NO 2.0(1.6-2.5) 1.6(1.4-1.9) 2.3(1.5-3.6) 2.1(1.3-3.4) 
Alcohol Never Drinker Ref Ref Ref Ref 
Former drinker 1.4(0.6- 3.8) 1.5(0.8-3.0) 0.9(0.6-1.5) 1(0.6-1.6) 
Current drinker 0.8(0.3-2.1) 0.8(0.3-2.1) 0.3(0.2-0.5) 0.4(0.2-0.6) 
Smoking Never smoker Ref Ref Ref Ref 
Former smoker 2.2(1.4-3.3) 2.5(1.8-3.2) 1.1(0.9-1.5) 1.3(0.9-1.8) 
Current smoker 1.8(1.2-2.7) 1.9(1.3-3.0) 0.7(0.5-1.2) 0.9(0.5-1.6) 
Marital status Single Ref Ref Ref Ref 
Married/Common 
Law  
2.1(1.7-2.5) 1.8(1.4-2.3) 0.96(0.7-1.2) 1.1(0.8-1.6) 
 
In both sexes, regardless of definition, no statically significant association was found 
between MetS and the income adequacy, employment status, smoking status, and marital 
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status in adjusted analysis.  In women, level of education was not statically associated 
with MetS according to either definition in adjusted analysis.  
As summarized in table 5, the results of adjusted analysis showed that older age and low 
level of physical activity are significant risk factors for the MetS regardless of gender and 
definition. According to the adjusted analysis, alcohol consumption is an additional 
significant protective factor, and higher level of education is an additional significant risk 
factor for women. In men, in adjusted analysis, retirement and being unemployed are 
additional risk factors. 
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Table 5. Multivariate odds ratios for variables significantly associated with 
Metabolic Syndrome among men and women, final model 
 MetS 
 OR( 95% CI) 
 Categories ATP III IDF 
Men    
AGE 18-24 Ref Ref 
25-34 2.9(1.4-6.1) 2.8(1.6-5.1) 
35-44 6.3(2.6-15.0) 6.6(3.4-13.0) 
45-54 11.0(4.6-25.8) 13.9(6.2-31.2) 
55-64 10.1(4.6-21.8) 12.2(6.1-242) 
65-74 8.6(3.3-22.8) 9.2(3.9-22.1) 
Exercise 
(≥ 1 time/week) 
Yes Ref Ref 
NO 2.0(1.5-2.8) 1.6(1.3-1.9) 
Employment status Full time Ref Ref 
Part time 0.8(0.5-1.4) 0.7(0.4-1.3) 
Unemployed 1.9(1.0-3.5) 1.9(1.0-3.4) 
Laid off  1.2(0.4-4.2) 0.2(0.1-0.6) 
Retired 2.1(1.1-3.8) 1.8(0.9-3.9) 
Other 0.5(0.1-2.3) 2.1(0.7-6.6) 
Home maker 1.1(0.2-5.8) 0.8(0.1-4.4) 
Student 0.4(0.1-3.7) 0.4(0.1-2.3) 
Women    
AGE 18-24 Ref Ref 
25-34 1.9(0.8-4.2) 1.7(0.8-3.6) 
35-44 6.2(2.6-14.9) 4.2(2.2-8.4) 
45-54 8.8(3.4-23.3) 6.8(3.0-15.4) 
55-64 9.7(4.7-19.9) 7.6(4.0-14.3) 
65-74 16.7(7.6-37.0) 16.1(7.7-34.0) 
Exercise 
(≥ 1 time/week) 
Yes Ref Ref 
NO 2.2(1.3-3.8) 2.0(1.2-3.5) 
Educational level 
 
Elementary Ref Ref 
Some secondary 0.7(0.4-1.1) 0.7(0.4-1.2) 
Secondary 0.5(0.3-0.7) 0.6(0.4-0.9) 
University degree 0.2(0.1-0.5) 0.3(0.1-0.6) 
Alcohol Never Drinker Ref Ref 
Former drinker 1.0(0.6-1.6) 1.1(0.6-1.9) 
Current drinker 0.5(0.4-0.7) 0.6(0.4-0.9) 
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4. Discussion 
There is no doubt that the risk of developing cardiovascular disease is higher in 
individuals with MetS than individuals without MetS (6,7,9,57,58), and MetS is one the 
major public health concerns in our societies today (59,60). Thus, identification of its 
associated risk factors could enable researchers and clinicians to implement 
interventional programs to reduce these risk factors, which should subsequently reduce 
the prevalence and incidence of MetS and result in benefits for patients and the public 
health care system (61).  
 Our results showed that the final model was the same based on the both definitions, but 
the magnitude of the association between risk factors and MetS was slightly different.  
Our results showed that the prevalence of MetS increases with age in both sexes, 
regardless of definition, as has been seen elsewhere (8,10,11,62,63). Park et al proposed 
that aging can lead to increase in the visceral adipose tissue and development of insulin 
resistance (14).  Compared to the ATP III definition, when the IDF definition was 
applied, prevalence of MetS was higher in all sex stratified age group. This finding was 
also observed by Hildrum et al in Norwegian population. As both definitions are based on 
the same components, the possible explanation for the difference in prevalence could be 
1.) the importance accorded to central obesity in the IDF definition, and/or 2.) the use of 
European, not American, WC cutoff points in our use of the IDF definition, which could 
have lead  to the identification of more individuals as being obese (8).   
Our results showed that risk of having MetS significantly linearly increased by age in 
unadjusted analysis, however, after adjusting for other risk factors, it reached its peak 
level between the age of 45 and 55.  
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Several studies found that the risk of developing MetS is lower among individuals who 
are physically active (12,28,31,32). In the present study, low level of physical activity 
was also a significant risk factor for the MetS regardless of gender in both adjusted and 
unadjusted analysis. This protective effect of physical activity is probably mediated 
through decreasing blood pressure level, triglyceride level, abdominal obesity and 
increasing HDL cholesterol level (30-35,44). 
Our results showed that alcohol consumption was a significant protective factor for 
women in both unadjusted and adjusted analysis.  The protective effect of moderate 
alcohol consumption also has been observed in several other studies (36). This protective 
effect could be due to the effect of moderate alcohol consumption on increasing HDL 
cholesterol level, decreasing blood pressure and insulin level, and improving insulin 
sensitivity (data is not shown) (44). However, there was no statistically significant 
association between alcohol consumption and MetS in men.  No association between 
alcohol consumption and MetS for both sexes has been reported in studies among 
Mediterranean, Irish, and Portuguese populations (31,45). Different sex-patterns 
regarding the effect of alcohol consumption have also found by Zhu et al in a study 
among the American Population (44). This gender difference regarding the effect of 
alcohol consumption can support the idea, suggested by Fan et al, that men are less 
susceptible to long-term health effect of alcohol than women (41). Indeed, higher dose of 
alcohol consumption in men appears to lead to adverse metabolic profiles.  
In women, we found that the level of education was inversely and significantly associated 
with MetS in both adjusted and unadjusted analysis. However, in men, this inverse 
association was statistically significant only in unadjusted analysis. This inverse 
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significant association that is observed only in women (not in men) is consistent with the 
results of several other studies in other populations (22,31,64). There are other studies 
that observed this inverse association in both men and women (25,26). However, Hye 
Park et al and Yong Park et al, in the studies among Korean and American adults, 
reported that there was no association between educational level and MetS in either sex 
(14,28). The explanation for the inverse association between educational level and MetS 
could be that the individuals with low educational levels are at the higher risk of 
developing of MetS- components that include hypertension, impaired glucose, diabetes, 
and overweight (14).  
Some researchers believe that the health impact of SES is affected by gender, as we 
found in this study. The potential reasons for this might be explained by Dallongeville et 
al 1) women are more health-oriented than men that help them to have better 
understanding about the health life style and 2).being educated can have more influence 
on food choices and health behaviors in women than men (25) 3) the association between 
SES and abdominal obesity is different between men and women, which might lead to 
different pattern of MetS as well. 
In the studies in the USA and France, level of income instead of educational level was 
reported as a significant risk factor for MetS (14,24), but in the present study this 
association was significant only in unadjusted analysis and only for women. The 
literature shows that individuals with low income level tend to have more undesirable 
health behaviors including unhealthier food choices, lack of physical activity, and lack of 
enough attention to their physical condition which would prone them to insulin 
resistance, dyslipidemia, and obesity (25,64). Thus we expect that the risk of developing 
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of MetS would be higher in both men and women with low level of income. However, 
some researchers argue that low income women are more likely vulnerable to the limited 
source of income than men (25). This could partially explain gender differences in the 
relationship between income level and MetS that was shown in the present and some 
other studies (25). 
Our results show that retirement and being unemployed (borderline significance by both 
definitions) are additional risk factors for men, as has been seen elsewhere (28). Our 
results also showed that, in women, being retired and self-defining themselves to be 
housewives were risk factors in developing of MetS in only unadjusted analysis, but not 
significant in the adjusted analysis. Possibly unemployment may lead to psychosocial 
stress that can induce the elevation of components of Metabolic Syndrome (24).  
We observed that the determinants of socioeconomic status, which can be considered as 
risk factors for developing MetS, are not same in men and women. This observation can 
support the hypothesis of Silventionen et al that education level and employment status 
“can lead to different results regarding the socioeconomic disparities in MetS” (23).   
Regardless of definition, smoking was a significant risk factor for MetS in men in 
unadjusted analysis, but not in adjusted analysis. Earlier studies have shown that smoking 
can cause dyslipidemia by inducing lipolysis, hypertension by stimulating sympathetic 
nerve activity, and insulin resistance by impairing insulin action, (28,31,46,50) thus 
clustering of these abnormalities or one might expect to observe a higher prevalence of 
MetS among smokers. In the present study, men who smoked had higher systolic and 
diastolic blood pressure, lower HDL level, higher TG level, and higher WC than non-
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smoking man, which may explain why smoking-men had a higher risk of having MetS 
than never-smoker men (data is not shown).  
In women, regardless of definition, the risk of having MetS was lower in smoking women 
than non-smoking women, but this association was not statistically significant.  
Onat et al in a study among 3385 Turkish people and Santos et al in a study among 2164 
Portuguese people reported that smokers had a lower risk of having MetS.  
They explained this protective effect could be due to the inverse relationship between 
smoking and obesity. In this study, the waist circumference of female smokers was 
smaller than waist circumference of female non-smokers (data is not shown).  
It has been shown that marriage can bring health benefits that lead to lower 
cardiovascular mortality and morbidity, however our results show that marriage or 
common-law marriage in men was a significant risk factor in only unadjusted analysis. 
A similar finding has been also reported by Hye Park et al, who found that unmarried 
men had lower risk of developing MetS than married men, although their association was 
not significant (28). Troxel et al explained that satisfaction of marriage can play an 
important role on the association between cardiovascular risk factors and marital status, 
thus being on unhappy relationship can lead to psychosocial stressor that can increase the 
risk of developing disease (51).  In the present study, married men had higher systolic 
and diastolic blood pressure, lower HDL level, higher TG level, and higher WC than 
single men.  
Troxel et al mentioned that the association between cardiovascular mortality and 
morbidity and marital status in women is less consistent than men. In the present study, 
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the association between marital status and MetS was not significant in women, regardless 
of definition. The paradox association, regarding the magnitude of their relation by using 
different definitions, was found in this study. When the ATP III applied, marriage was a 
protective factor, while it was a risk factor when the IDF applied. Hye Park et al also 
reported that risk of developing MetS was statistically higher among unmarried women 
(64). 
This study has several limitations, first in this study the classification of Metabolic 
Syndrome relied on patient report of a physician diagnosis of diabetes, rather than 
measured fasting blood glucose. This issue can lead to underestimation of the prevalence 
of DM (65), and have an underestimation of the prevalence of MetS.   
Second, we had no information on the ethnicity of participants in this study so we could 
not use the ethnic-specific cutoff point for central obesity, which should be used to define 
MetS by the IDF definition. Thus this issue can lead to misclassification of individuals as 
having MetS; however, according to census data by statistic Canada 86% of population 
were Caucasian in 1991, so this would likely not have had a major impact. Third, there 
was no information about the lipid lowering drugs so individuals who were treated for 
hypertriglyceridemia were not considered as having dyslipidemia. This limitation can 
lead to underestimation of the true prevalence of dyslipidemia, and subsequently 
underestimation of prevalence of MetS. Fourth, this study was based on the individuals 
for whom full anthropometric measurements and data on all components of MetS were 
available and we excluded individuals for whom those information was not available, 
thus there is possibility of selection bias in this study. Finally, it is a cross-sectional so a 
causal association cannot be inferred from these findings. 
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5. Conclusion  
Demographic, socio economic factors, and lifestyle habits are significantly associated 
with MetS among the Canadian adults. The socioeconomic factors which are associated 
with Metabolic Syndrome vary by gender; level of educational appears to be the best 
measure in women versus employment status in men.  Physical activity is associated with 
lower odds of MetS for both sexes; it might be expected therefore that intervention 
programs to increase the level of physical activity among the Canadian population may 
reduce the prevalence of MetS. 
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Abstract 
Background: No studies have compared the ability of ATP III and IDF to predict CVD 
mortality among Canadian adults using the National Cholesterol Education Program 
(NCEP) Adult Treatment Panel (ATP III) and the International Diabetes Federation (IDF) 
definitions.  
Objective: The purpose of this study was to determine the effect of definition on the 
prevalence of the component factors by using the ATP III and the IDF definitions and 
examine the relation between Metabolic Syndrome and CVD mortality. 
Methods: The Canadian Heart Health Survey was a cross-sectional probability  
sample survey conducted in all 10 Canadian provinces between 1986 and 1992.  Statistics 
Canada linked the CHHS data set to Canadian Mortality Database. The present study is 
based on 2553 men and 2644 women from three provinces (Alberta, Manitoba, and 
Saskatchewan) for whom full anthropometric measurements, mortality data, and data on 
all components of MetS were available. MetS was defined according to ATP III and IDF 
definitions. Cox-regression analyses using the STATA (version11) was conducted.    
Results: In women who have the Metabolic Syndrome  according to the IDF definition 
81.9%, 76.6%, 71.7%, and 14.4% have low high-density cholesterol, high triglyceride, 
hypertension, and diabetes,  respectively, versus 84.5%, 80.3%, 78.4%, and 19.3% 
according to ATP III (p≤0.001).   In men, the comparable levels of prevalence are 71.7%, 
85.1 %, 71.5%, and 10.5% according to IDF and 78.7%, 89.3%, 85.0%, and 13.1% 
according to ATP III (p≤0.001). Kappa agreements between the definitions are 70.8% for 
men and 82.3% for women (p≤0.05).  The hazards of death due to CVD events in women 
with the syndrome according to the ATP III and the IDF definitions are 3.96(1.30-12.09) 
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and 2.56 (1.32-4.97), respectively. The comparable numbers for men are 2.21(1.16-4.02) 
and 2.50(1.50-4.17). 
Conclusion:  The prevalence of MetS is higher when the IDF definition is applied but the 
metabolic derangement of individuals identified is less severe. The ATP III definition 
predicts CVD mortality better in women, while the IDF definition predicts CVD 
mortality better in men.  
 
 
Key words: Metabolic Syndrome, insulin resistance syndrome, insulin resistance, 
definition, Cardiovascular disease mortality. 
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1. Introduction 
During the past decade, several definitions have been developed for Metabolic Syndrome 
(1-4) and several studies used these definitions to describe the prevalence of the 
Metabolic Syndrome in different countries (2).  The results showed that the prevalence 
was varied and it was difficult to compare these studies because different definitions were 
used, the ways that they modified the definitions were different, and their study designs 
were different as well (1,2). Several studies compared the prevalence of the syndrome by 
applying different definitions and measured the degree of concordance between these 
definitions during the past years (5-11). Most studies aimed to compare the prevalence of 
MetS using ATP and IDF definitions, reported a higher prevalence based on IDF 
definition.  
Several studies have examined the association between the Metabolic Syndrome and 
cardiovascular disease (CVD). Most studies have used the WHO and the ATP III 
definitions to examine this association (12-15), and fewer studies used the IDF (16-22) 
and the AACE definitions (19). 
Among the above studies, four notable meta-analyses have reported that that risk of 
developing the CVD was higher in individuals with Metabolic Syndrome than those 
without the syndrome (12-15). Three meta-analyses included studies which used both the 
ATP III and the WHO definitions (12-14), and one meta-analysis only included studies 
which used the ATP III (15). Other studies which used the IDF, (16-22), and the AACE 
definitions (19) also reported a similar association.  
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One important scientific dilemma was that several definitions can lead to confusion 
among researchers and clinicians. Thus, researchers and clinicians should know which 
definition can be more useful and practical and there is also a need for a unified definition 
(6-10,23-28). One of the best ways to address the issues prevented by different 
definitions is to compare their predictive accuracy for disease, particularly CVD 
development. Indeed, one of the main reasons for proposing different definitions of 
Metabolic Syndrome was to identify individuals who were at a higher risk for developing 
cardiovascular disease. Thus, by comparing the predictive accuracy of the definition for 
developing CVD, researchers sought to determine which definition should be used in 
both clinical practice and research (19). 
Several studies were conducted to examine the comparison. The results of three meta-
analysis showed that the WHO definition could predict cardiovascular events better than 
the ATP III definition (12-14). The results of studies which compared the ATP III and the 
IDF definitions were varied. Some studies reported that the ATP III was superior in 
predicting CVD events than the IDF definition in both sexes (18,21).However the results 
of study by Katzmarzyk showed that they had the same ability in men (16). Benetos et al 
reported that the IDF was a better predictor than the ATP III (20). The result of a study 
by Qiao et al found that theta  predicted CVD events better than the IDF in men, while in 
women the IDF was superior(17). However, these studies varied regarding the baseline 
population, follow up years, number of CVD events, how they modified the definitions, 
and different potential confounders which had been controlled in their analysis (19). 
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It has been known that CVD is one of the most important causes of death in Canada, and 
some predicted that earlier the risk of developing CVD is higher in individuals with the 
syndrome. The prevalence of the Metabolic Syndrome is high in Canada, but is varied 
among different studies (men 15.9%, women 19.2%) (29-31).Thus, there is a need for a 
precise definition which can identify individuals with the Metabolic Syndrome accurately 
in Canadian populations. Although several definitions have been developed, the most 
applicable in both clinical practice and research are the ATP III and the IDF definitions.  
To our knowledge, no studies have compared the ability of ATP III and IDF to predict 
CVD mortality among Canadian adults. This study determined the prevalence of 
Metabolic Syndrome by using the ATP III and the IDF definitions and examined the 
relation between Metabolic Syndrome and CVD mortality in Canadian adults. 
 
2. Methods 
Baseline study 
The Canadian Heart Heath Survey (CHHS) was a cross-sectional study which was 
conducted between 1986 and 1992 in ten provinces. Details of the study have been 
published previously (32). Participants were non-institutionalized Canadians, aged 18-74. 
The health insurance registration files were used to choose participants. The study was 
conducted at two stages. Participants, who agreed to be involved in the study, were 
visited by a trained nurse at their home.  The nurses measured blood pressure at the 
beginning and end of the visit. Participants were also asked to fill in a questionnaire 
which included the questions regarding CVD risk factors, and attitudes and opinions of 
participants about heart health related issues. Within two weeks, participants presented to 
 130 
a survey clinic. During the clinic visit, the nurses measured blood pressure at the 
beginning and end of the visit, and took the blood sample. The means of four blood 
pressures, which were measured during the home interview and clinic visit, were 
calculated during the data analysis. The blood sample was sent to the Lipid Research 
Laboratory at the University of Toronto to measure the lipid profile, which included low 
density lipoprotein cholesterol (LDL), high density lipoprotein (HDL), and Triglycerides 
(TG). Participants wore indoor clothing without shoes to measure the anthropometric 
components. Standard protocols were applied to measure waist circumference (32). The 
level of narrowing waist circumference was measured at the end of normal expiration.  
WC was measured at the level of the floating rib if nurses could not find the level of 
narrowing waist circumference. Although height and weight were only measured in all 
ten provinces, waist circumference was measured in five provinces (Alberta, Manitoba, 
Ontario, Quebec and Saskatchewan). Blood glucose was not measured, however 
participants were considered diabetic if they have been told by a doctor that they had 
diabetes. Type I and II were not distinguished.  
Age was considered into two categories (<65, ≥65 year). Smoking status was considered 
in three categories including: never-smokers (participants who never smoked), former-
smokers (participants who had stopped smoking), and current-smokers (participants who 
smoke at least one cigarette every day). Drinking status was categorized as former 
drinkers (participants who had stopped drinking), and current drinkers (participants who 
reported alcohol drinking during the past month). Participants who reported they never 
drank alcohol were excluded due to the small numbers in this category.  Participants were 
classified into two groups regarding their physical activity status. If participants did not 
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engage in physical activity during the previous month of the study for at least half an 
hour, they were considered as sedentary individuals, otherwise they were considered 
active individuals.  Socioeconomic variables (education level, income level, and 
employment status) were considered in the analysis. Level of education of participants 
divided into two categories: participants with less than secondary education, and 
participants with secondary education or university degree. Participants were categorized 
into three income adequacy levels: low, middle, and high (Details have been published 
previously) (32). Participants were asked regarding their employment status and they 
were categorized into three categories: fulltime or part time, retired, and other which 
included unemployment, laid-off, home makers, and students. The rationale for grouping 
participants into three categories regarding their employment status was to have sufficient 
numbers of deaths due to CVD in each group. Marital status was classified as single 
(which included never married, widowed, and divorced) or married (which included 
married and common-law marriage). 
 
Follow-up study 
Statistics Canada linked the CHHS data set to Canadian Mortality Database (CMDB). 
The CMDB record all deaths since 1950, and these are regularly updated by using death 
registrations which are reported by all Canadian provinces and territories. Record linkage 
was performed using computerized probabilistic match. There is a national health care 
system in Canada and CMDB covers the entire population, so the chance of missing 
death events for participants was limited. The present study is based on 2553 men and 
2644 women from three provinces (Alberta, Manitoba, and Saskatchewan) for whom full 
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anthropometric measurements, bootstrap weights, and data on all components of MetS 
were available. In the study, participants were followed up from date of survey to 
December 31/ 2004. The CHHS was a complex survey design, so Statistics Canada 
calculated the bootstraps weights for the participants based on the PSU (probability 
sample unit) and strata, which enabled researchers to calculate an accurate value of 
standard error. During the linkage process the Statistics Canada changed the ID number 
of participants for confidentiality purposes. As a result, three data sets were released by 
the Statistics Canada including: mortality data set, bootstrap-weights data set, and the 
original CHHS with new ID numbers. Three data sets were merged together during the 
data analysis process according to the ID numbers.  The cause of death was reported by 
the Statistics Canada according to Intentional Classification of Disease (ICD), 9 th (up to 
December 31 1999) and 10th (up to December 31 2004) codes revisions. Cardiovascular 
events were identified during the data analysis by the researchers (ICD-9: 390-448; ICD-
10: 100-178). If there was no information regarding the death events, participants were 
considered alive. 
The Metabolic Syndrome was defined using a modification of the criteria from the  
ATP III (33) and IDF Definitions (Tables 1a,1b) (4).   No information was available 
about the ethnicity of participants, and according to Statistic Canada more than 85 % of 
Canadian populations were Caucasian in 1991. Thus, the European cutoff point was 
applied to define the central obesity in the IDF definition. There was no information 
available about lipid lowering drugs, so individuals who were under treatment for 
dyslipidemia with normal lipid profile were not have been identified as dyslipidemic. 
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Fasting blood glucose was not measured so diagnosis of diabetes was based on physician 
diagnosis of diabetes.  
 
Table 1 a. ATP III definition of Metabolic Syndrome  
Metabolic Syndrome :  
At least three of the following:  
 
 Central obesity( waist circumference ≥ 102cm for men and ≥ 88 cm for women) 
 Triglyceride≥ 1.7 mmol/L 
 HDL< 1.03 mmol/L(men) ; HDL<1.3 mmol/L(women) 
 Blood pressure ≥ 130/85mmHg; or Drug treatment for hypertension 
 Physician diagnosis of diabetes 
* adopted from ATP III definition 
 
 
Table 1b. IDF Definition of Metabolic Syndrome   
Metabolic Syndrome :  
 
Central obesity (defined as waist circumference exceeding specific values)*   
Plus any two of the following four factors: 
Raised triglycerides:  ≥150 mg/dL (1.7 mmol/L)  
Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in men < 50 mg/dL 
(1.30mmol/L) in women  
Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension 
Physician diagnosis of diabetes 
 
*Ethnicity-specific values were not available; European cutoff point was applied:  
  Men WC≥94; Women WC≥80 
* adopted from IDF definition 
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Statistical analyses 
The CHHS is a complex survey design. Standard statistical methods that assume that the 
data represent a simple random sample are not appropriate. To accommodate the complex 
survey design, our analysis was conducted using STATA (version11) (StataCorp. 2009. 
Stata Statistical Software: Release 11. College Station, TX: StataCorp LP) that enabled 
researchers to perform Cox-regression analyses using the bootstrap weights to estimate 
the standard error (StataCorp. 2009. Stata Statistical Software: Release 11. College 
Station, TX: StataCorp LP). Twelve individuals were excluded from the analysis because 
there was a disconcordance regarding their gender between the CHHS and mortality data 
set. Four individuals excluded from analysis because the date of death was reported 
before the date of the survey. Individuals who died during the follow-up time due to non-
cardio vascular causes of were excluded from the analysis (men 285 (10%), women 190 
(6.7%)). Descriptive statistics were based on a weighted analysis in order to produce 
nationally representative and unbiased estimates. Follow-up time based on the date of 
survey and end date of follow up was calculated. The survey Cox-regression procedure, 
adjusted for age, the level of education, income adequacy, employment status, alcohol 
drinking status, smoking status, marital status, and LDL cholesterol, was used to estimate 
the association between Metabolic Syndrome and CVD mortality.  Separate models were 
examined for men and women. Crude and adjusted hazard ratios and 95% CI were 
calculated. Interaction terms and confounding were examined as well. The assumption of 
proportional hazards was evaluated by graphic diagnostics tools.  
Kappa agreement was calculated to analyze the concordance between the two definitions 
based on unweighted numbers.  Kappa values were considered to be excellent (≥0.8), 
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good (0.61-080), moderate (0.41-0.60), and weak (≤0.40). The SAS Proc Frequency was 
used to test the difference between proportion for each components involved in the 
definition of MetS.  
 
3. Results 
The characteristics of participants are summarized in tables 2a and 2b according to both 
definitions. 2553 men and 2644 women are included in the study. Individuals (both men 
and women) with the syndrome are older, have higher systolic and diastolic blood 
pressure, lower HDL level, higher TG and BMI than those without the syndrome. 
Compared to women, men with the syndrome are younger, have lower systolic blood 
pressure, lower HDL level and BMI, while their TG, diastolic blood reassure, and WC 
levels are higher. 
Table 2a.  Descriptive statistics (mean± se) for MetS-components (men).   
 MEN (MEAN±SE) MEN (MEAN±SE) 
 ATP III IDF 
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
AGE 38.02±13.82 47.18±13.69 37.63±13.72 45.56±13.78 
Average SBP 122.41±12.29 135.90±12.65 122.36±12.35 133.08±13.43 
Average DBP 77.59±8.65 86.02±8.54 77.53±8.81 84.36±8.53 
HDL 1.21±0.27 0.93±0.18 1.22±0.28 0.96±.019 
TG 1.40±0.80 2.78±1.88 1.35±0.79 2.63±1.70 
WC 89.21±9.87 104.54±11.49 88.35±9.80 104.22±9.16 
BMI 25.41±3.67 30.05±4.25 25.12±3.53 30.04±3.97 
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Table 2b. Descriptive statistics (mean± se) for MetS-components (women). 
 WOMEN (MEAN±SE) WOMEN (MEAN±SE) 
 ATP III IDF 
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
AGE 38.74±13.84 52.74±13.88 38.53±13.70 51.62±14.52 
Average SBP 114.15±13.81 136.32±16.60 113.96±13.90 133.87±16.66 
Average DBP 71.93±8.52 82.71±8.31 71.82±8.59 81.59±8.29 
HDL 1.45±0.33 1.11±0.23 1.45±0.33 1.12±0.24 
TG 1.15±0.57 2.42±1.08 1.13±0.56 2.31±1.04 
WC 75.83±10.00 95.94±13.16 75.47±10.03 94.64±12.10 
BMI 23.94±4.00 31.35±5.64 23.82±4.00 30.83±5.34 
 
The prevalence of Metabolic Syndrome according to the IDF and the ATP III definitions 
are 21.9%, 17.1% in men and 16.7%, 14.2% in women, respectively. Cross tabulation of 
individual by the two definitions shows that 77.3% of women and 66% of men with the 
Metabolic Syndrome are identified by both definitions. The results show that 22.7 % of 
women and 34% of men who have been identified as individuals with the syndrome by 
the IDF definition, have been identified as normal individuals by the ATP III definition. 
The results also showed that 1.5% of women and 3.3% of men who have been identified 
as normal subjects according to the IDF definition, have the syndrome according to the 
ATP III definitions. Kappa agreements between the definitions are 70.8% for men and 
82.3% for women (p≤0.05).   
Table3a demonstrates the prevalence of the Metabolic Syndrome according to different 
risk factors. Indeed, a significant association has been reported between these factors and 
Metabolic Syndrome and CVD. As it is shown, the prevalence of the syndrome is higher 
according to the IDF definition than the ATP III definition for every risk factor. Table 3b 
shows the percentage mortality due to CVD or other causes for different risk factors.   
Higher numbers of deaths are observed for individuals who are older, retired, inactive, 
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current smokers, have stopped drinking alcohol, are married, or have lower level of 
education. The percentages of CVD deaths are higher in men with middle income and 
women with low income. 
Out of 2883 men and 2834 women who participated in the study, 3.2% (183) and 5.6% 
(285) of men died due to CVD and other causes during the follow-up (15 years) . The 
comparable numbers for women are 1.9% (103) and 4.8% (190). Out of 737 men and 633 
women who had the Metabolic Syndrome according to the IDF definition, 7 % (96) men 
and 5.8% (58) died due to CVD. Out of 613 men and 560 women who have the 
Metabolic Syndrome according to the ATP III definition, 6.9% (84) and 7.0% (52) died 
due to CVD.  
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Table 3a. Prevalence of Metabolic Syndrome by sex and different risk factors 
 Men Women 
 weighted %  weighted % 
 ATP III IDF ATP III IDF 
AGE <65 16.0 20.7 12 14.2% 
>=65 32.1 38.4 36 42.9 
Income 
adequacy 
Low 16.9 22.4 20.6 23.8 
Middle 17.8 23.5 15.5 19.3 
High 15.1 19.0 7.9 9.1 
Educational 
level 
Elementary or 
Some secondary 
26.7 31.3 25.5 26.9 
Secondary or  
University degree 
13.7 18.6 10.3 13.3 
Employment 
status 
Full-time or Part- 
time 
15.9 20.6 9.1 12.0 
Retired 33.7 40.7 34.2 39.6 
Unemployed or 
Laid off or  
Home maker or  
Student or Other  
12.5 16.4 18.8 20.3 
Exercise 
(≥ 1 time/week) 
Yes 14.7 18.9 14.3 16.4 
No 20.8 26.7 13.9 17.2 
Alcohol Former drinker 21.2 31.3 26.0 25.9 
Current drinker 16.7 20.9 12.3 15.2 
Smoking Never smoker 12.9 16.9 12.9 16.7 
Former smoker 22.1 26.7 16.4 18.1 
Current smoker 14.8 21.7 14.1 15.6 
Marital status Single 9.6 13.3 14.5 17.6 
Married  20.3 25.6 14.0 16.4 
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Table 3b. Overall status of participants at the end of follow-up  
 Men Women 
 weighted % weighted % 
 Other 
cause 
CVD 
death 
Alive Other 
cause 
CVD 
death 
Alive 
Age <65 3.3 1.5 94.6 3.3 0.7 96.0 
>=65 23.9 22.5 53.6 18.3 12.6 69.1 
Income 
adequacy 
Low 6.3 2.3 91.3 4.1 2.5 93.3 
Middle 6.7 4.7 88.6 5.9 2.0 92.1 
High 3.5 1.8 94.8 3.0 1.1 96.0 
Educational 
level 
Elementary or 
Some secondary 
11.8 7.5 80.7 8.5 4.7 86.8 
Secondary or  
University degree 
3.2 1.6 95.2 3.5 1.0 95.5 
Employment 
status 
Full-time or Part- 
time 
3.5 1.9 94.6 2.7 0.5 96.8 
Retired 21.8 16.1 7.2 13.9 10.3 75.8 
Unemployed or 
Laid off or 
Home maker or  
Student or  
Other 
4.8 0.8 94.4 6.5 2.5 91.1 
Exercise 
(≥ 1 time/week) 
Yes 5.9 3.2 90.8 4.3 1.7 93.9 
No 5.1 3.3 91.7 5.8 2.4 91.8 
Alcohol Former drinker 9.8 4.9 58.3 7.7 5.7 86.5 
Current drinker 5.3 3.1 91.7 4.1 1.3 94.6 
Smoking Never smoker 2.7 1.2 96.1 5.1 1.7 93.2 
Former smoker 6.4 4.9 88.7 3.7 2.1 94.2 
Current smoker 8.1 2.2 89.7 6.3 2.4 91.3 
Marital status Single 3.6 2.1 94.3 5.9 1.6 92.4 
Married  6.4 3.7 89.9 4.4 2.1 93.5 
Overall  Mortality  5.6 3.2 91.1 4.8 1.9 93.2 
 
Table 4 describes the prevalence of the components of the Metabolic Syndrome 
according to both definitions in both sexes. As it is shown, ATP III definition identifies 
people with a more adverse metabolic profile. In women who have the Metabolic 
Syndrome  according to the IDF definition 81.9%, 76.6%, 71.7%, and 14.4% have low 
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high-density cholesterol, high triglyceride, hypertension, and diabetes,  respectively, 
versus 84.5%, 
80.3%, 78.4%, and 19.3% according to ATP III (p≤0.001).   In men, the comparable 
levels of prevalence are 71.7%, 85.1 %, 71.5%, and 10.5% according to IDF  
and 78.7%, 89.3%, 85.0%, and 13.1% according to ATP III (p≤0.001). 
 
Table 4.  Prevalence of MetS-Components by ATPIII and IDF definition stratified 
by sex.  
 MEN WOMEN 
IDF ATP III IDF ATP III 
 Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Normal Metabolic 
Syndrome  
Low HDL* 20.8% 71.7% 22.3% 78.7% 31.7% 81.9% 32.7% 84.5% 
TG≥1.7 20.0% 85.1% 23.0% 89.3% 10.7% 76.6% 12.0% 80.3% 
HTN** 27.8% 71.5% 27.6% 85.0% 13.2% 71.7% 13.8% 78.4% 
DM 1.9% 10.5% 1.9% 13.1% 3.5% 14.4% 3.0% 19.3% 
Elevated 
WC*** 
24.8% 100% 8.8% 69.6% 26.9% 100% 11.5% 76.8% 
*Low HDL for men: HDL <1.03, women: HDL<1.3 
** Blood pressure ≥ 130/85mmHg or anti hypertensive treatment 
***Elevated WC by ATP III for men: WC≥102; for women WC≥88 
***Elevated WC by IDF for men: WC≥94; for women: WC≥80 
**** The difference of proportions of the two definitions is statistically significant (p≤ 
0.001) for all components. 
 141 
 
Table 5a, 5b present the hazard ratios of CVD mortality associated with the Metabolic 
Syndrome. According to the multivariable models, the hazards of dying due to CVD 
events in women who have the syndrome according to the ATP III and the IDF 
definitions are 3.96 (1.30-12.09) and 2.56 (1.32-4.97), respectively. The comparable 
numbers for men are 2.21 (1.16-4.02) and 2.50 (1.50-4.17). Regardless of the definitions, 
in women, the hazards of death due to CVD are higher in those who are older, inactive, 
current smokers, former drinkers, and retired. In men, regardless of the definitions, the 
hazards of death due to CVD are higher in those who are older, current smokers, and of 
middle income. 
Interaction terms between the Metabolic Syndrome and other risk factors was examined, 
which none of them was statistically significant. In women, regardless of definition, age 
was a confounding factor. In men, when the IDF definition and the ATP III definitions 
were applied, smoking and income were confounding factors, respectively.   
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Table 5a. Hazard ratios for CVD mortality associated with the Metabolic Syndrome 
by both definitions in women, final model.   
                                    CVD mortality 
 Categories HR (95% CI) 
WOMEN  
 
  
ATP III No Ref 
Yes 3.96(1.30-12.09) 
AGE * <65 Ref 
>=65 6.18(1.49-25.59) 
EXERCISE 
 (≥ 1 time/week) 
Yes Ref 
No 1.63(1.01-2.64) 
SMOKING Never smoker Ref 
Former smoker 2.17(1.09-4.31) 
Current smoker 3.68(1.89-7.18) 
ALCHOL  Former drinker Ref 
Current drinker 0.39(0.20-0.78) 
EMPLOYMENT 
STATUS 
Full-time or Part- time Ref 
Retired 4.53(1.12-18.38) 
Unemployed or Laid off or Student or 
Home maker or Other 
2.09(0.51-8.55) 
WOMEN  
 
  
IDF No Ref 
Yes 2.56 (1.32-4.97) 
AGE * <65 Ref 
>=65 6.40(1.63-25.21) 
EXERCISE 
 
Yes Ref 
No 1.68(1.05-2.68) 
SMOKING Never smoker Ref 
Former smoker 2.17(1.08-4.35) 
Current smoker 3.74(1.89-7.40) 
ALCHOL  Former drinker Ref 
Current drinker 0.35(0.17-0.75) 
EMPLOYMENT 
STATUS 
Full-time or Part- time Ref 
Retired 5.03(1.27-19.97) 
Unemployed or Laid off or Student or 
Home maker or Other 
2.20(0.57-8.53) 
*confounding factor 
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Table 5b. Hazard ratios for CVD mortality associated with the Metabolic Syndrome 
by both definitions in men, final model.   
 CVD mortality  
 Categories HR (95% CI) 
MEN  
 
  
ATP III No Ref 
Yes 2.21(1.16-4.02) 
AGE  <65 Ref 
>=65 20.58 (10.61-39.89) 
SMOKING * Never smoker Ref 
Former smoker 1.93(0.98-3.72) 
Current smoker 2.26(1.08-4.76) 
EDUCATIONAL LEVEL Elementary or Some secondary Ref 
Secondary or University degree 0.70(0.47-1.03) 
INCOME Low Ref 
Middle 1.74(1.00-3.01) 
High  1.49(0.65-3.34) 
MEN  
 
  
IDF No Ref 
Yes 2.50(1.50-4.17) 
AGE  <65 Ref 
>=65 20.14(10.20-39.78) 
SMOKING Never smoker Ref 
Former smoker 1.81(0.93-3.54) 
Current smoker 2.20(1.02-4.71) 
EDUCATIONAL LEVEL Elementary or Some secondary Ref 
Secondary or University degree 0.68(0.48-0.96) 
INCOME ADEQUACY * Low Ref 
Middle 1.81(1.05-3.11) 
High  1.51(0.66-3.48) 
*confounding factor 
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4. Discussion 
 
One of the main concerns among researchers and clinicians is having a unified definition 
which can identify precisely individuals with the Metabolic Syndrome (6-10,23-28). To 
our knowledge it is the first attempt to examine the association between the Metabolic 
Syndrome and CVD mortality in Canadian adults by using the ATP III and the IDF 
definitions, and compared the predictive power of these two definitions for the CVD 
mortality.  
The results show that the prevalence of the Metabolic Syndrome is lower in women than 
men which is consistent with the result of other studies (11). The results also showed that 
the prevalence of the Metabolic Syndrome was lower according to the ATP III than the 
IDF definition.  This finding has also been observed in several other studies (5-11). There 
could be two main reasons for having a lower prevalence of the syndrome according to 
the ATP III definition: the use of the European WC cut-off value (94, 80 cm), not 
American, in the IDF definition; or the indication of WC as a main obligatory component 
in the IDF definition (5).     
As observed in several other studies (7,11,24), the concordance between the IDF and the 
ATP III definition is good in this study (Kappa statistics for men: 70.8% Kappa statistics 
for women: 82.3%). These findings are not surprising because the essential components 
of these definitions are the same (7,11,24). 
In the present study, the ATP III definition identifies people with a more adverse 
metabolic profile including:  blood pressure, TG, LDL cholesterol, and HDL cholesterol. 
The similar results also observed by Olijhoek et al (10). These results raise the question 
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regarding the prognostic implication of these two definitions. To answer this question, we 
compared the definitions regarding their predictive accuracy for the CVD mortality. 
In this study, the CVD mortality is higher in individuals with the syndrome than those 
without the syndrome. These results also have been observed in several studies 
(12-22). In four notable meta-analyses by Ford et al, Galassi et al, Gami et al, and 
Mottillo et al the pooled relative risks (RRs)  for developing the cardiovascular events in 
individuals with the syndrome according to the ATP III were 1.74, 1.6, 1.35, and 2.35 
respectively(12-15). Three of these studies separately reported the pooled RRs for men 
and women. Galassi et al reported that the RR for developing the CVD events were 1.5 in 
men and 2.1 in women(13), and the RRs  which reported by  Gami et al and Mottillo et al  
were 1.89  and 1.94 in men , and 2.63 and 2.55 in women, respectively (14). In the 
present study the hazard ratios for CVD mortality are 3.96 in women and 2.21 in men 
with the Metabolic Syndrome according to the ATP III definitions. Observing higher 
HRs in the present study compared to other studies might be due to the inclusion of 
diabetic individuals in the present study. Indeed, in a Meta –analysis by Ford et al, the 
authors observed that those studies which included diabetic individuals had higher pooled 
RRs for developing CVD events compared with those studies which did not included 
individuals with diabetes (2.2 vs 1.58). In fact, individuals with established diabetes have 
more CVD risk factors which can lead to developing higher CVD events. In addition to 
this explanation, the base line populations, end point definitions, methods for analysis, 
duration of follow-up, confounders which have been considered, and the way that the 
Metabolic Syndrome definitions have been modified in the present study are different 
from other studies. All these issues might explain why higher HRs have been observed in 
 146 
the present study (19). Similarly, hazards of CVD mortality for individuals with the 
syndrome as per the IDF definition are higher in the present study compared to other 
studies (men HR=2.50, women HR=2.56) (16-21). The same explanation might justify 
the difference between the results of this study and other studies.  
In the present study, regardless of definitions, the hazard of CVD mortality in women 
with the Metabolic Syndrome  is higher than men with the syndrome, as seen elsewhere 
(13,14). Although there is no clear explanation for this observation, several theories have 
been proposed (15). Mottillo et al discussed that central obesity had a greater adverse 
effect on the risk of CVD events in postmenopausal women than men. Also, level of LDL 
increases and LDL becomes denser in postmenopausal women, which increases the risk 
of CVD events in women more than men (15). Mottillo et also discussed that the 
elevation of TG could lead to more coronary artery disease in women than men (15).  
Huxley et al, in a meta-analysis, reported that coronary heart disease mortality was higher 
in diabetic women than diabetic men by 50%.(34). A greater adverse effect of diabetes in 
women than men could be due to several reasons. Several studies showed that diabetic 
women had a more adverse metabolic profile (34,35) and diabetic women were less likely 
to receive medications (statins, aspirin and anti- hypertensive medication) than diabetic 
women (34). Also, unfavorable cardiac risk factors had more impact on diabetic women 
than diabetic men (35). Thus, higher hazards of CVD events in women than men might 
be due to the inclusion of subjects with diabetes in the present study. 
The results show that the ATP III definition predicts CVD mortality better in women, 
whereas the IDF definition can predict CVD mortality better in men. As explained 
earlier, having different end points, considering different confounding factors, using 
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different modified definitions, and not stratifying results by gender lead to discrepancies 
among different studies regarding the predictive accuracy of the different definitions (22). 
Thus, comparing the results is difficult.  
Our results show that the ATP III definition (3.96) can predict the CVD mortality better 
than the IDF definition (2.56) in women. Similar results were observed in studies among 
non-diabetic Swedish adults (18) and Korean adults (21). In another non-population 
based study, Saley et al also observed that the ATP III definition could predict the 
coronary artery events better than the IDF definition (36). Results of the present study 
show that the ATP III definition identifies women with adverse metabolic profile, and 
IDF definition fails to identify non-obese women have a high risk of developing the CVD 
events. In addition, hypertension and low HDL level had the strongest association with 
CVD events compared to other components in women (37,38). Regitz-Zagrosek, in 
addition to low HDL level, reported that high TG level had a greater effect in developing 
CVD events than other components in women (39). Thus, based on these results the 
criteria of the IDF definition in women should be modified because, as explained earlier, 
it fails to identify women who have a high CVD mortality risk.  
Our results showed that the IDF definition better predicts CVD events than the ATP III 
definition in men (2.21 vs 2.50). Results that are both consistent (16,20,22)and 
inconsistent with this finding have been reported (17).  Several studies reported that 
among the components of Metabolic Syndrome, hypertension and abdominal obesity had 
the strongest association with development of CVD in men (37,39). Also, our results 
confirm the importance of abdominal obesity as a key factor in developing of CVD 
events. Katzmarzyk et al in a study in non-Hispanic American men pointed out that the 
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IDF definition failed to identify a large proportion of not abdominally obese men 
(WC<94), who had other risk factors and were at a high mortality risk. Thus, they 
suggested that there is a need to modify the WC threshold (16).  However, the results of 
the present study show that the presence abdominal obesity (WC ≥94, women WC≥80) in 
combination with other risk factors can accurately predict CVD mortality in Canadian 
adults. The comparison must be taken with caution because the characteristics of the 
population are different.  
The present study has several strengths. First, the present study is based on large sample 
size and a population which represents the general Canadian population. Second, our 
study has a large number of deaths and a long follow-up period, which increases the 
power of the study (19). Several important confounders have been considered in the 
present study. However, the present study has several limitations.  Diagnosis of diabetes 
was based on physician diagnosis which can lead to an underestimation of its prevalence 
and subsequently the prevalence of the syndrome (40). Also, including individuals with 
diabetes leads to higher hazards of developing of CVD mortality in subjects with the 
syndrome. There is lack of information regarding the ethnicity of participants which can 
lead to misclassification of individuals as having MetS. There is no information available 
about lipid lowering drugs which lead to underestimation of prevalence of dyslipidemia. 
Individuals who do not have full anthropometric measurements are excluded, which raise 
the concern of selection bias. Individuals who died due to other causes were also 
excluded from analysis which might raise some concern regarding the accuracy of the 
analysis. However, individuals who die due to other causes can not be considered as 
censored because other causes of death are the competing events but censoring means 
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that events will happen at a later time. In addition, the goal of this study is to compare the 
predictive accuracy of the definition for development of the CVD. To ease the confusion 
regarding the analysis, the competing- risk procedure is performed, and the results show 
that the final models and hazard ratios are slightly different (data is not shown).    
 
Conclusion  
The prevalence of MetS is higher when the IDF definition is applied but the metabolic 
derangement of individuals identified is less severe. The ATP III definition predicts CVD 
mortality better in women, while the IDF definition predicts CVD mortality better in 
men.  
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4. Conclusions and future research  
 
The present thesis examine, the prevalence of the Metabolic Syndrome  by the IDF and 
ATP III definitions, the degree of concordance between the definitions, the associated 
risk factors for the Metabolic Syndrome , the association between the syndrome and CVD 
mortality, and the predictive accuracy of the definitions for CVD mortality. 
Several definitions have been developed during the past decades (3), and it has been well 
documented that individuals with the Metabolic Syndrome at a higher risk of developing 
cardiovascular disease, regardless of definition (21,22,40,87-94). Moreover, the main 
reason to identify individuals with the Metabolic Syndrome is to identify individuals who 
are at a risk of developing CVD events, however labeling many individuals with a 
diagnosis of the Metabolic Syndrome leads to burden on patients and public health care 
system (3,27,91). Although several studies have conducted in the USA and Europe on the 
Metabolic Syndrome, there is little information available for Canadian adults. The results 
of this study provide useful information for clinicians and researchers to assess the 
importance of the syndrome, to identify individuals who are at a risk of CVD events, and 
to identify associated risk factors. Thus, public health professional and clinicians can 
implement interventional programs to reduce the prevalence and incidence of the 
Metabolic Syndrome which would be expected subsequently reduce CVD mortality in 
Canadian populations.  
As explained previously, the primary intention of our studies was to include all 
individuals for whom full anthropometric measurements were obtained which included 
only five provinces (Alberta, Manitoba, Ontario, Quebec and Saskatchewan). However, 
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Statistics Canada completed the linkage of the CHHS data set with the mortality data set 
and provided the necessary bootstrap weights for only three provinces (Alberta, 
Manitoba, and Saskatchewan). As a result, the sample size was reduced for our third 
objective. On the other hand, the research question of first paper is also covered briefly in 
third paper. Obviously, the results are similar because the analysis was conducted on 
subpopulation. In this section, results regarding prevalence of the syndrome, the degree 
of concordance between definitions, and the predictive accuracy of the definitions will be 
discussed together, while the associated risk factors will be discussed separately.  
 
I. Degree of concordance between two definitions  
 The results show that the prevalence of the Metabolic Syndrome to be higher in men 
(ATP III; 17.9%, IDF: 23.8 %) than women (ATP III; 15.3%%, IDF: 17.3%), which is 
consistent with several studies (11). In two Canadian studies, conducted by Arden et al 
(32)and Brien et al (36), in which ATP III definitions have been applied the prevalence of 
the Metabolic Syndrome  is 17 % and 17.5 % in men and 13.2% and 11.2% in women.  
However, in a recent Canadian study, Riediger et reported that the prevalence of MetS 
was 15.9 in men and 19.5 in women (43). Based on these results, we conclude that there 
is a need for public health initiatives to reduce the prevalence of MetS in Canadian adults 
with more emphasis on women.  
Although the essential components of both definitions are the same, the prevalence of the 
syndrome is higher when the IDF definition applied, as has been observed by others 
(3,11,23-27). This result can be understood by the examining differences in the 
definitions. In fact, in the IDF definition abdominal obesity (WC) is a required 
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component and its cut-off value is lower compared to the ATP definition (23).  In the 
present study the European cut-off value has been applied because there is the lack of 
information regarding the ethnicity of our population and according to the Statistics 
Canada 86% of the Canadian population was Caucasian in 1991(Statistics Canada) . 
There is lack of information regarding the WC threshold for Canadian people. Thus, we 
recommend that defining the WC threshold in Canadian population should be subject of 
future research.  
The results also show that individuals who are identified by the IDF definition have a less 
adverse cardiovascular metabolic profile with respect to blood pressure, LDL, and HDL. 
However, a higher prevalence of the syndrome is observed by using the IDF definition 
(men; ATP III; 17.9%, IDF: 23.8 %, women; ATP III; 15.3%%, IDF: 17.3%). There is 
also a body of research that suggests that abdominal obesity is the first component which 
develops before other components of the Metabolic Syndrome (100) and many obese 
individuals who are metabolically normal might develop insulin resistance later in their 
life (101). These results raise the questions as to which definition can identify accurately 
individuals who are at a higher risk of developing CVD events, and whether applying the 
IDF definition would label more individuals as unhealthy.  Several studies attempted to 
answer these issues by comparing the concordance between definitions 
(3,11,23,25,27,29,31,37-39), and comparing their predictive accuracy in development of 
CVD events (21,22,40,87-94).  
The results of this study show that the degree of concordance between the IDF and the 
ATP III definition is good (men: 72 %, women: 80%, p≤0.05), which is consistent with 
several other studies (11,25,29).  However, the degree of concordance between the 
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definitions does not provide information regarding the prognostic value of these two 
definitions. To investigate this issue, the association between the syndrome and CVD 
mortality, and the predictive accuracy of definitions for CVD mortality need to be 
investigated. 
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II. Predictive accuracy of definitions 
The results show that regardless of definition individuals with the syndrome have a 
higher mortality due to CVD events than those without syndrome (men: ATP III=2.21, 
IDF=2.50; women ATP III =3.96, IDF=2.56) . These findings confirm the importance of 
the Metabolic Syndrome in mortality from CVD, which has been also observed in several 
other studies (21,22,40,87-94). Several studies have been conducted in Europe, America, 
and Asia, but there is little information available for Canadian population. We suggest 
that the comparison between the definitions regarding their accuracy to predict CVD 
mortality should be considered for the future research in Canadian population.  
As discussed earlier, several studies compared the prognostic value of different 
definitions (21,22,40,87-94). But the results of these studies should be compared with 
caution. Indeed, baseline population, duration of follow up, and definition of end points 
are different. In addition, each study modifies the definitions differently and different 
confounders are considered in their analyses which lead to difficulty in the interpretation 
of the results (89). Overall, these issues strongly suggest that there is a need for unified 
definition which can be used by all researchers and clinicians. In addition, most studies 
compares the prognostic implication of the ATP III and WHO definitions (21,22,87,88), 
and there is less information available regarding the comparison of the ATP III and IDF 
definitions (40,89-93). Also, to our knowledge no study compares the predictive accuracy 
of these two definitions in Canadian adults. Thus, the present study provides useful 
information regarding the health consequences of Metabolic Syndrome in Canadian 
population.  
 161 
Higher hazards of death due to CVD events are observed in the present study compared 
to the results of other studies for both sexes (men: ATP III=2.21, IDF=2.50; women:  
ATP III =3.96, IDF=2.56) (21,22,40,87-94). In addition to differences between the 
present and other studies (89), it has been well documented that including diabetic 
individuals in our study leads to observing higher CVD events in subjects with the 
Metabolic Syndrome (87). Thus, these reasons might explain the difference between the 
results of this study and other studies.  
The results show that although the prevalence of the Metabolic Syndrome is higher in 
men (ATP III; 17.1 %, IDF: 21.9 %) than women (ATP III; 14.2 %, IDF: 16.7%), the 
hazard of death due to CVD is higher in women (ATP III =3.96, IDF=2.56) than men 
(ATP III=2.21, IDF=2.50). Several theories have been developed to explain why women 
with the syndrome more likely to die due to CVD events (88). It has been discussed that 
central obesity has greater adverse effects in developing CVD in women than men. Also, 
high TG level cause more coronary artery disease in women than men, and diabetic 
women have higher coronary heart disease mortality than diabetic men (88,102,103). 
These results suggest that the intervention programs, which reduce prevalence and 
incidence of the Metabolic Syndrome in Canada, should focus more on women. Also, 
Riediger et al recently reports one in five on Canadian adults have MetS, which confirm 
the importance of intervention programs to reduce the prevalence of MetS in Canada 
(43).  
Although the ATP definition identifies individuals with a more adverse metabolic profile 
in both sexes, the prognostic implication of the ATP III and IDF definitions are different 
between men (ATP III=2.21, IDF=2.50) and women(ATP III =3.96, IDF=2.56).  The 
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ATP III definition identifies women with a more adverse metabolic profile, and predicts 
CVD mortality better than the IDF definition. These results might suggest that 
cardiovascular metabolic profile is more important than abdominal obesity in women, as 
the IDF definition is highly influenced by the presence of abdominal obesity. In addition, 
most studies report stronger associations between low HDL level and high level TG with 
CVD mortality compared to other components of the Metabolic Syndrome in women 
(95,104,105). These results might suggest that the IDF criteria should be modified for 
Canadian women with more emphasis on cardiovascular metabolic profile and less 
emphasize on abdominal obesity. In men, the ATP III definition identifies men with a 
more adverse metabolic profile but the IDF definition predicts CVD mortality better. 
Several studies report that among the components of the Metabolic Syndrome, the 
strongest associations are observed between hypertension and abdominal obesity and 
CVD events (104,105). These results suggest that abdominal obesity, as explained by 
Cameron et al and Sims et al, is a key component and the first component which develops 
before other components in men (100,101). However, concluding which definition is 
superior in Canadian adults should be with caution. Indeed, there is little information 
available in Canada. Also, the results regarding the predictive accuracy of the IDF and 
the ATP definitions for CVD events are varied (40,89-93).  
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III. Associated risk factors   
Obesity and CVD are important issues among Canadian population. 60% of Canadian are 
overweight and obese and  almost 30% of women and 31% of men die each year due to 
CVD in Canada ( 1 Statistics Canada, CANSIM Table 102-0529: Deaths, by cause, 
Chapter IX: Diseases of the circulatory system (I00 to I99), age group and sex, Canada, 
annual (number), 2000 to 2006. Released May 4, 2010). As discussed earlier, the 
association between Metabolic Syndrome and CVD events are well documented in the 
present and several other studies (21,22,40,87-94). Thus, identifying associated risk 
factors for Metabolic Syndrome is an important issue in Canada. In fact, researchers will 
be able to implement intervention programs to reduce the prevalence and incidence of the 
Metabolic Syndrome by knowing the risk factors (9). However, there is little information 
available in Canada regarding the risk factors of Metabolic Syndrome. The association 
between several well known risk factors and Metabolic Syndrome is examined in this 
thesis.  
The present results show that the prevalence of the Metabolic Syndrome is age dependent 
and reaches its peak between the age of 45 and 55 in both men and women. The 
increasing risk of developing the Metabolic Syndrome by age might be due to increasing 
the abdominal obesity or insulin resistance by age (48,106). These results suggest the 
importance of weight reduction in individuals with the syndrome. The American Hearth 
Association recommends that individuals with the syndrome should be physically active 
and their diet should be low in saturated and trans fats, cholesterol, sodium, and 
carbohydrate (3,9).    
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The results also show that the risk of developing the Metabolic Syndrome in physically 
active individuals is less than sedentary individuals (men; ATP III: OR= 2.0(1.5-2.8); 
IDF: OR=1.6(1.3-1.9), women; ATP III OR = 2.2(1.3-3.8), IDF= 2.0(1.2-3.5). Also, 
higher numbers of death due to CVD are observed for sedentary individuals (men; 
ATPIII: HR= 20.8 %; IDF: HR =26.7 %, women; ATP III=13.9%; IDF=17.2%). Our 
results in combination with the results of other studies (49,55,64,66) confirm the 
importance of physical activity in individuals with the Metabolic Syndrome.  The 
American Hearth Association recommends individuals with the syndrome should be 
engaged in moderate-intensity activities for at least 30 min for five days per week (9). 
Thus, applying this recommendation will have undeniable benefits for Canadian adults 
with the syndrome.  
The results of the present study show that the consumption of alcohol consumption have 
a protective effect for the development the Metabolic Syndrome only in women (ATP III: 
OR=0.5(0.4-0.7), IDF: OR=0.6(0.4-0.9)). The association between alcohol consumption 
and the syndrome is complex and contradicting associations have been reported (55,57-
59). In the present study the classification of alcohol consumption relied on self-report 
questioners and there is no information regarding the quantity and types of alcoholic 
beverage which might lead to bias (107). All these issues suggest that interpretation of 
the results should be interpreted with caution.   
The association between socioeconomic status and Metabolic Syndrome is varied 
between studies and also is different between men and women. Moreover, there is not an 
agreement which measure of socioeconomic status are better predictors for the 
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development of the Metabolic Syndrome (48,49,55,59,65,77-80).  The results of present 
study show that education level in Canadian women (University degree; ATP III: OR=0.2 
(0.1-0.5); IDF:OR= 0.3(0.1-0.6), Secondary education ; ATP III OR=0.5(0.3-0.7) , IDF 
OR=0.6(0.4-0.9)) employment status  (retired: ATP III: OR=2.1(1.1-3.8), IDF: OR=1.8 
(0.9-3.9)) in Canadian men have significant associations with developing the Metabolic 
Syndrome . No significant association is observed between income level and risk of 
developing the Metabolic Syndrome. Our results confirm the importance of education in 
women (80) and employment in men (49) as protective factors for development of the 
Metabolic Syndrome. In fact, they can reduce development of each components of the 
syndrome (48,65). Riediger et al also confirmed that Canadian people with low level of 
education and income have higher risk to develop MetS (43).  
The association between smoking and the Metabolic Syndrome is statistically significant 
only in unadjusted analysis. However, smoking is a risk factor in men (current smoker: 
ATP; III OR=1.8 (1.2-2.7), IDF; OR= 1.9(1.3-3.0)) and protective factor in women 
(current smoker: ATP III; OR=0.7 (0.5-1.2), IDF; OR= 0.9 (0.5-1.6)). Observing the 
different magnitude of association between smoking and the Metabolic Syndrome may be 
due to different effect of smoking on abdominal obesity (56) and cardiovascular 
metabolic profile (49,51-54). Although the present results do not demonstrate a 
significant association between smoking and the Metabolic Syndrome, smoking is a well 
know risk factor for cardiovascular disease. Thus, we suggest that, as it was discussed by 
the American Hearth Association, smokers who have the Metabolic Syndrome should 
quit smoking (9).  
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In married men higher odds of developing of Metabolic Syndrome (ATP III; 
OR=2.1(1.7-2.5), IDF; OR=1.8(1.4-2.3)) and in married women both higher (IDF; 
OR=1.1(0.8-1.6) and lower odds (ATP III: OR=0.96(0.7-1.2)) of developing the 
syndrome are observed in unadjusted analysis.  However, these associations are not 
significant in adjusted analysis in this study.  It has been discussed that being married 
could lead to a lower cardiovascular mortality and morbidity (49,69). On the other hand, 
to our knowledge there is little information available regarding the association between 
the marital status and the Metabolic Syndrome.  We suggest that investigation of this 
association should be considered for future research. 
 
IV. Future research  
It has been discussed that the primary goal of clinical management of individuals with 
Metabolic Syndrome is to reduce the risk of atherosclerotic disease by reducing LDL 
cholesterol level, controlling hypertension, and preventing diabetes (9). Theses goals can 
be achieved through lifestyle modification or drug therapies. In terms of lifestyle 
modification, weight reduction by reducing caloric intake and increasing physical activity 
has been suggested. However, there is a need for strategies which help individuals with 
the Metabolic Syndrome to achieve and sustain these goals for long term. Statins for 
treatment of dyslipidemia and Angiotension-Converting Enzyme (ACE) inhibitors for 
treatment of hypertension have been suggested. To our knowledge there is not enough 
evidence available regarding the primary use of these drugs in individuals with the 
Metabolic Syndrome, and also more investigation are needed in terms of cost 
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effectiveness of using theses drugs (9). More research should be done to find the most 
appropriate therapies for individuals with the Metabolic Syndrome.   
As we discussed earlier, there is little known about the association between the Metabolic 
Syndrome and CVD events by using all definitions, the predictive accuracy of these 
definitions, and associated risk factors for Metabolic Syndrome in Canadian population. 
Thus, we suggest that these subjects should be considered for future research in Canadian 
population. These information help researchers and clinicians to identify individual with 
the syndrome accurately and also design a good interventional program to reduce the 
prevalence of the syndrome.  
It has been reported that there are number of metabolic changes which occur in 
individuals with Metabolic Syndrome such as elevations of CRP, inflammatory cytokines 
(IL-6), fibrinolytic factors (plasminonogen activator inhibator-1), clotting factors 
(fibrinogn), and reduction of adiponectin. Although, measurement of these factors is not 
easily available in clinical practice, there is a need for more investigation regarding the 
association between these proinflammatory and prothrombotic factors and Metabolic 
Syndrome because it will provide more information about the pathogenesis of the 
syndrome.  It has been shown that there are numbers of different ways which measure 
body fat distribution such as; using dual-energy x-ray absorptiometry (DXA), CT or 
MRI, measuring adipose tissue biomarkers (leptin, adiponectin), measuring liver fat 
(using resonance spectroscopy). Also, there are some other anthrogenic factors which can 
measure dyslipidemia such as; apolipoprotein B, small LDL particles, triglycerides/ 
HDL-c ratios. Additional research is needed to better refine which of these measurements 
should be applied in the definition (9). 
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